BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, Blosser RL, Fan H, Wang H, Luber BS, Zhang M, Papadopoulos N, Kinzler KW, Vogelstein B, Sears CL, Anders RA, Pardoll DM, Housseau F. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov 2015;5:43-51. [PMID: 25358689 DOI: 10.1158/2159-8290.CD-14-0863] [Cited by in Crossref: 742] [Cited by in F6Publishing: 502] [Article Influence: 92.8] [Reference Citation Analysis]
Number Citing Articles
1 Kersten K, Salvagno C, de Visser KE. Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy. Front Immunol 2015;6:516. [PMID: 26500653 DOI: 10.3389/fimmu.2015.00516] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 6.4] [Reference Citation Analysis]
2 Jacobs J, Smits E, Lardon F, Pauwels P, Deschoolmeester V. Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect. J Immunol Res 2015;2015:158038. [PMID: 26605342 DOI: 10.1155/2015/158038] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
3 Goel G. Molecular characterization and biomarker identification in colorectal cancer: Toward realization of the precision medicine dream. Cancer Manag Res 2018;10:5895-908. [PMID: 30510457 DOI: 10.2147/CMAR.S162967] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
4 Yuan H, Ji J, Shi M, Shi Y, Liu J, Wu J, Yang C, Xi W, Li Q, Zhu W, Li J, Gong X, Zhang J. Characteristics of Pan-Cancer Patients With Ultrahigh Tumor Mutation Burden. Front Oncol 2021;11:682017. [PMID: 33968789 DOI: 10.3389/fonc.2021.682017] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Jacobs J, Deschoolmeester V, Zwaenepoel K, Flieswasser T, Deben C, Van den Bossche J, Hermans C, Rolfo C, Peeters M, De Wever O, Lardon F, Siozopoulou V, Smits E, Pauwels P. Unveiling a CD70-positive subset of cancer-associated fibroblasts marked by pro-migratory activity and thriving regulatory T cell accumulation. Oncoimmunology 2018;7:e1440167. [PMID: 29900042 DOI: 10.1080/2162402X.2018.1440167] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
6 Pauken KE, Dougan M, Rose NR, Lichtman AH, Sharpe AH. Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities. Trends Immunol 2019;40:511-23. [PMID: 31053497 DOI: 10.1016/j.it.2019.04.002] [Cited by in Crossref: 74] [Cited by in F6Publishing: 64] [Article Influence: 24.7] [Reference Citation Analysis]
7 Li M, Kaili D, Shi L. Biomarkers for response to immune checkpoint inhibitors in gastrointestinal cancers. World J Gastrointest Oncol 2022; 14(1): 19-37 [DOI: 10.4251/wjgo.v14.i1.19] [Reference Citation Analysis]
8 Roberts J, Salaria SN, Cates J, Wang Y, Vnencak-Jones C, Berlin J, Shi C. PD-L1 Expression Patterns in Microsatellite Instability-High Intestinal Adenocarcinoma Subtypes. Am J Clin Pathol 2019;152:384-91. [PMID: 31152546 DOI: 10.1093/ajcp/aqz052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
9 Carethers JM. Microsatellite Instability Pathway and EMAST in Colorectal Cancer. Curr Colorectal Cancer Rep. 2017;13:73-80. [PMID: 28367107 DOI: 10.1007/s11888-017-0352-y] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 6.2] [Reference Citation Analysis]
10 Gang W, Wang JJ, Guan R, Yan S, Shi F, Zhang JY, Li ZM, Gao J, Fu XL. Strategy to targeting the immune resistance and novel therapy in colorectal cancer. Cancer Med 2018;7:1578-603. [PMID: 29658188 DOI: 10.1002/cam4.1386] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
11 Chen X, Chen J, Feng Y, Guan W. Prognostic Value of SLC4A4 and its Correlation with Immune Infiltration in Colon Adenocarcinoma. Med Sci Monit 2020;26:e925016. [PMID: 32949121 DOI: 10.12659/MSM.925016] [Reference Citation Analysis]
12 Bindal P, Gray JE, Boyle TA, Florou V, Puri S. Biomarkers of therapeutic response with immune checkpoint inhibitors. Ann Transl Med 2021;9:1040. [PMID: 34277840 DOI: 10.21037/atm-20-6396] [Reference Citation Analysis]
13 Kleponis J, Skelton R, Zheng L. Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors. Cancer Biol Med 2015;12:201-8. [PMID: 26487965 DOI: 10.7497/j.issn.2095-3941.2015.0046] [Cited by in F6Publishing: 38] [Reference Citation Analysis]
14 Cohen R, Pudlarz T, Delattre JF, Colle R, André T. Molecular Targets for the Treatment of Metastatic Colorectal Cancer. Cancers (Basel) 2020;12:E2350. [PMID: 32825275 DOI: 10.3390/cancers12092350] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
15 Baxter MA, Middleton F, Cagney HP, Petty RD. Resistance to immune checkpoint inhibitors in advanced gastro-oesophageal cancers. Br J Cancer 2021. [PMID: 34230609 DOI: 10.1038/s41416-021-01425-7] [Reference Citation Analysis]
16 Kim JH, Seo MK, Lee JA, Yoo SY, Oh HJ, Kang H, Cho NY, Bae JM, Kang GH, Kim S. Genomic and transcriptomic characterization of heterogeneous immune subgroups of microsatellite instability-high colorectal cancers. J Immunother Cancer 2021;9:e003414. [PMID: 34903553 DOI: 10.1136/jitc-2021-003414] [Reference Citation Analysis]
17 Nosho K, Sukawa Y, Adachi Y, Ito M, Mitsuhashi K, Kurihara H, Kanno S, Yamamoto I, Ishigami K, Igarashi H, Maruyama R, Imai K, Yamamoto H, Shinomura Y. Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer. World J Gastroenterol 2016; 22(2): 557-566 [PMID: 26811607 DOI: 10.3748/wjg.v22.i2.557] [Cited by in CrossRef: 154] [Cited by in F6Publishing: 138] [Article Influence: 25.7] [Reference Citation Analysis]
18 Gaillard SL, Secord AA, Monk B. The role of immune checkpoint inhibition in the treatment of ovarian cancer. Gynecol Oncol Res Pract 2016;3:11. [PMID: 27904752 DOI: 10.1186/s40661-016-0033-6] [Cited by in Crossref: 89] [Cited by in F6Publishing: 82] [Article Influence: 14.8] [Reference Citation Analysis]
19 Giordano G, Parcesepe P, D'Andrea MR, Coppola L, Di Raimo T, Remo A, Manfrin E, Fiorini C, Scarpa A, Amoreo CA, Conciatori F, Milella M, Caruso FP, Cerulo L, Porras A, Pancione M. JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer. J Exp Clin Cancer Res 2019;38:28. [PMID: 30670049 DOI: 10.1186/s13046-018-1019-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
20 Greten TF, Wang XW, Korangy F. Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches. Gut. 2015;64:842-848. [PMID: 25666193 DOI: 10.1136/gutjnl-2014-307990] [Cited by in Crossref: 97] [Cited by in F6Publishing: 105] [Article Influence: 13.9] [Reference Citation Analysis]
21 Park HE, Kim JH, Cho NY, Lee HS, Kang GH. Intratumoral Fusobacterium nucleatum abundance correlates with macrophage infiltration and CDKN2A methylation in microsatellite-unstable colorectal carcinoma. Virchows Arch. 2017;471:329-336. [PMID: 28597080 DOI: 10.1007/s00428-017-2171-6] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 7.6] [Reference Citation Analysis]
22 You W, Shang B, Sun J, Liu X, Su L, Jiang S. Mechanistic insight of predictive biomarkers for antitumor PD‑1/PD‑L1 blockade: A paradigm shift towards immunome evaluation (Review). Oncol Rep 2020;44:424-37. [PMID: 32627031 DOI: 10.3892/or.2020.7643] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
23 Sacdalan DB, Lucero JA. The Association Between Inflammation and Immunosuppression: Implications for ICI Biomarker Development. Onco Targets Ther 2021;14:2053-64. [PMID: 33776452 DOI: 10.2147/OTT.S278089] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Hamada T, Nowak JA, Masugi Y, Drew DA, Song M, Cao Y, Kosumi K, Mima K, Twombly TS, Liu L, Shi Y, da Silva A, Gu M, Li W, Nosho K, Keum N, Giannakis M, Meyerhardt JA, Wu K, Wang M, Chan AT, Giovannucci EL, Fuchs CS, Nishihara R, Zhang X, Ogino S. Smoking and Risk of Colorectal Cancer Sub-Classified by Tumor-Infiltrating T Cells. J Natl Cancer Inst 2019;111:42-51. [PMID: 30312431 DOI: 10.1093/jnci/djy137] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
25 Nie H, Nie D, Men L. Role of miR-214 in modulating proliferation and invasion of human colon cancer SW620 cells. Oncol Lett 2018;16:7175-9. [PMID: 30546454 DOI: 10.3892/ol.2018.9521] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
26 Golshani G, Zhang Y. Advances in immunotherapy for colorectal cancer: a review. Therap Adv Gastroenterol 2020;13:1756284820917527. [PMID: 32536977 DOI: 10.1177/1756284820917527] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 11.5] [Reference Citation Analysis]
27 Poturnajova M, Furielova T, Balintova S, Schmidtova S, Kucerova L, Matuskova M. Molecular features and gene expression signature of metastatic colorectal cancer (Review). Oncol Rep 2021;45:10. [PMID: 33649827 DOI: 10.3892/or.2021.7961] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
28 Jin KT, Chen B, Liu YY, Lan HU, Yan JP. Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer. Cancer Cell Int 2021;21:83. [PMID: 33522929 DOI: 10.1186/s12935-021-01763-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
29 Almasabi S, Ahmed AU, Boyd R, Williams BRG. A Potential Role for Integrin-Linked Kinase in Colorectal Cancer Growth and Progression via Regulating Senescence and Immunity. Front Genet 2021;12:638558. [PMID: 34163519 DOI: 10.3389/fgene.2021.638558] [Reference Citation Analysis]
30 Xu T, Chai J, Wang K, Jia Q, Liu Y, Wang Y, Xu J, Yu K, Zhao D, Ma J, Fan L, Yan Q, Guo S, Chen G, Chen Q, Xiao H, Liu F, Qi C, Liang R, Li M, Wang Z. Tumor Immune Microenvironment Components and Checkpoint Molecules in Anaplastic Variant of Diffuse Large B-Cell Lymphoma. Front Oncol 2021;11:638154. [PMID: 34221962 DOI: 10.3389/fonc.2021.638154] [Reference Citation Analysis]
31 Domblides C, Soubeyran I, Lartigue L, Mahouche I, Lefort F, Velasco V, Barnetche T, Blanco P, Déchanet-Merville J, Faustin B. Prognostic Role of Inflammasome Components in Human Colorectal Cancer. Cancers (Basel) 2020;12:E3500. [PMID: 33255437 DOI: 10.3390/cancers12123500] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Tang J, Jiang W, Liu D, Luo J, Wu X, Pan Z, Ding P, Li Y. The comprehensive molecular landscape of the immunologic co-stimulator B7 and TNFR ligand receptor families in colorectal cancer: immunotherapeutic implications with microsatellite instability. Oncoimmunology. 2018;7:e1488566. [PMID: 30288357 DOI: 10.1080/2162402x.2018.1488566] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
33 Dong D, Lei H, Liu D, Bai H, Yang Y, Tang B, Li K, Liu J, Xu G, Xiao X. POLE and Mismatch Repair Status, Checkpoint Proteins and Tumor-Infiltrating Lymphocytes in Combination, and Tumor Differentiation: Identify Endometrial Cancers for Immunotherapy. Front Oncol 2021;11:640018. [PMID: 33816285 DOI: 10.3389/fonc.2021.640018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Cohen R, Shi Q, André T. Immunotherapy for Early Stage Colorectal Cancer: A Glance into the Future. Cancers (Basel) 2020;12:E1990. [PMID: 32708216 DOI: 10.3390/cancers12071990] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Xiang R, Fu J, Ge Y, Ren J, Song W, Fu T. Identification of Subtypes and a Prognostic Gene Signature in Colon Cancer Using Cell Differentiation Trajectories. Front Cell Dev Biol 2021;9:705537. [PMID: 34966734 DOI: 10.3389/fcell.2021.705537] [Reference Citation Analysis]
36 Zarkavelis G, Boussios S, Papadaki A, Katsanos KH, Christodoulou DK, Pentheroudakis G. Current and future biomarkers in colorectal cancer. Ann Gastroenterol 2017;30:613-21. [PMID: 29118555 DOI: 10.20524/aog.2017.0191] [Cited by in Crossref: 22] [Cited by in F6Publishing: 42] [Article Influence: 4.4] [Reference Citation Analysis]
37 Goldstein JB, Wu W, Borras E, Masand G, Cuddy A, Mork ME, Bannon SA, Lynch PM, Rodriguez-Bigas M, Taggart MW, Wu J, Scheet P, Kopetz S, You YN, Vilar E. Can Microsatellite Status of Colorectal Cancer Be Reliably Assessed after Neoadjuvant Therapy? Clin Cancer Res 2017;23:5246-54. [PMID: 28522602 DOI: 10.1158/1078-0432.CCR-16-2994] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
38 Xu J, Hu Z, Zhou H. Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer-Beyond the Misdiagnosis. JAMA Oncol 2019;5:739-40. [PMID: 30973582 DOI: 10.1001/jamaoncol.2019.0518] [Reference Citation Analysis]
39 Lin H, Wei S, Hurt EM, Green MD, Zhao L, Vatan L, Szeliga W, Herbst R, Harms PW, Fecher LA, Vats P, Chinnaiyan AM, Lao CD, Lawrence TS, Wicha M, Hamanishi J, Mandai M, Kryczek I, Zou W. Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. J Clin Invest 2018;128:805-15. [PMID: 29337305 DOI: 10.1172/JCI96113] [Cited by in Crossref: 207] [Cited by in F6Publishing: 147] [Article Influence: 51.8] [Reference Citation Analysis]
40 Au TH, Wang K, Stenehjem D, Garrido-Laguna I. Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies. J Gastrointest Oncol 2017;8:387-404. [PMID: 28736627 DOI: 10.21037/jgo.2017.01.04] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
41 Schmitt M, Greten FR. The inflammatory pathogenesis of colorectal cancer. Nat Rev Immunol 2021. [PMID: 33911231 DOI: 10.1038/s41577-021-00534-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
42 Jin Z, Sinicrope FA. Prognostic and Predictive Values of Mismatch Repair Deficiency in Non-Metastatic Colorectal Cancer. Cancers (Basel) 2021;13:300. [PMID: 33467526 DOI: 10.3390/cancers13020300] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
43 Kobori T, Tanaka C, Tameishi M, Urashima Y, Ito T, Obata T. Role of Ezrin/Radixin/Moesin in the Surface Localization of Programmed Cell Death Ligand-1 in Human Colon Adenocarcinoma LS180 Cells. Pharmaceuticals (Basel) 2021;14:864. [PMID: 34577564 DOI: 10.3390/ph14090864] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Bao X, Zhang H, Wu W, Cheng S, Dai X, Zhu X, Fu Q, Tong Z, Liu L, Zheng Y, Zhao P, Fang W, Liu F. Analysis of the molecular nature associated with microsatellite status in colon cancer identifies clinical implications for immunotherapy. J Immunother Cancer. 2020;8. [PMID: 33028695 DOI: 10.1136/jitc-2020-001437] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
45 Lu Z, Zhao Z, Cheng P, Huang F, Guan X, Zhang M, Chen H, Liu Z, Jiang Z, Zheng Z, Zou S, Wang X. B7-H3 immune checkpoint expression is a poor prognostic factor in colorectal carcinoma. Mod Pathol 2020;33:2330-40. [DOI: 10.1038/s41379-020-0587-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
46 Lazarus J, Maj T, Smith JJ, Perusina Lanfranca M, Rao A, D'Angelica MI, Delrosario L, Girgis A, Schukow C, Shia J, Kryczek I, Shi J, Wasserman I, Crawford H, Nathan H, Pasca Di Magliano M, Zou W, Frankel TL. Spatial and phenotypic immune profiling of metastatic colon cancer. JCI Insight 2018;3:121932. [PMID: 30429368 DOI: 10.1172/jci.insight.121932] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
47 Maletzki C, Beyrich F, Hühns M, Klar E, Linnebacher M. The mutational profile and infiltration pattern of murine MLH1-/- tumors: concurrences, disparities and cell line establishment for functional analysis. Oncotarget 2016;7:53583-98. [PMID: 27447752 DOI: 10.18632/oncotarget.10677] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
48 Teng MW, Galon J, Fridman WH, Smyth MJ. From mice to humans: developments in cancer immunoediting. J Clin Invest 2015;125:3338-46. [PMID: 26241053 DOI: 10.1172/JCI80004] [Cited by in Crossref: 157] [Cited by in F6Publishing: 83] [Article Influence: 22.4] [Reference Citation Analysis]
49 Zhou Z, Xie X, Wang X, Zhang X, Li W, Sun T, Cai Y, Wu J, Dang C, Zhang H. Correlations Between Tumor Mutation Burden and Immunocyte Infiltration and Their Prognostic Value in Colon Cancer. Front Genet 2021;12:623424. [PMID: 33664769 DOI: 10.3389/fgene.2021.623424] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
50 Wang M, Busuttil RA, Pattison S, Neeson PJ, Boussioutas A. Immunological battlefield in gastric cancer and role of immunotherapies. World J Gastroenterol 2016; 22(28): 6373-6384 [PMID: 27605873 DOI: 10.3748/wjg.v22.i28.6373] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
51 Wang Y, Bhave MS, Yagita H, Cardell SL. Natural Killer T-Cell Agonist α-Galactosylceramide and PD-1 Blockade Synergize to Reduce Tumor Development in a Preclinical Model of Colon Cancer. Front Immunol 2020;11:581301. [PMID: 33193386 DOI: 10.3389/fimmu.2020.581301] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
52 Hino H, Shiomi A, Kusuhara M, Kagawa H, Yamakawa Y, Hatakeyama K, Kawabata T, Oishi T, Urakami K, Nagashima T, Kinugasa Y, Yamaguchi K. Clinicopathological and mutational analyses of colorectal cancer with mutations in the POLE gene. Cancer Med 2019;8:4587-97. [PMID: 31240875 DOI: 10.1002/cam4.2344] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
53 Climent M, Ryan ÉJ, Stakelum Á, Khaw YL, Creavin B, Lloyd A, Alhassan D, Mohan HM, Kennelly R, Sheahan K, Winter DC. Systemic inflammatory response predicts oncological outcomes in patients undergoing elective surgery for mismatch repair-deficient colorectal cancer. Int J Colorectal Dis 2019;34:1069-78. [PMID: 30993458 DOI: 10.1007/s00384-019-03274-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
54 Inoue A, Robinson FS, Minelli R, Tomihara H, Rizi BS, Rose JL, Kodama T, Srinivasan S, Harris AL, Zuniga AM, Mullinax RA, Ma X, Seth S, Daniele JR, Peoples MD, Loponte S, Akdemir KC, Khor TO, Feng N, Roszik J, Sobieski MM, Brunell D, Stephan C, Giuliani V, Deem AK, Shingu T, Deribe YL, Menter DG, Heffernan TP, Viale A, Bristow CA, Kopetz S, Draetta GF, Genovese G, Carugo A. Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer. Gastroenterology 2021;161:196-210. [PMID: 33745946 DOI: 10.1053/j.gastro.2021.03.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Thompson ED, Zahurak M, Murphy A, Cornish T, Cuka N, Abdelfatah E, Yang S, Duncan M, Ahuja N, Taube JM, Anders RA, Kelly RJ. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut. 2017;66:794-801. [PMID: 26801886 DOI: 10.1136/gutjnl-2015-310839] [Cited by in Crossref: 206] [Cited by in F6Publishing: 217] [Article Influence: 34.3] [Reference Citation Analysis]
56 Credle JJ, Itoh CY, Yuan T, Sharma R, Scott ER, Workman RE, Fan Y, Housseau F, Llosa NJ, Bell WR, Miller H, Zhang SX, Timp W, Larman HB. Multiplexed analysis of fixed tissue RNA using Ligation in situ Hybridization. Nucleic Acids Res 2017;45:e128. [PMID: 28854731 DOI: 10.1093/nar/gkx471] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
57 Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18:1182-1191. [PMID: 28734759 DOI: 10.1016/s1470-2045(17)30422-9] [Cited by in Crossref: 1020] [Cited by in F6Publishing: 613] [Article Influence: 204.0] [Reference Citation Analysis]
58 Meireson A, Chevolet I, Hulstaert E, Ferdinande L, Ost P, Geboes K, De Man M, Van de Putte D, Verset L, Kruse V, Demetter P, Brochez L. Peritumoral endothelial indoleamine 2, 3-dioxygenase expression is an early independent marker of disease relapse in colorectal cancer and is influenced by DNA mismatch repair profile. Oncotarget 2018;9:25216-24. [PMID: 29861865 DOI: 10.18632/oncotarget.25393] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
59 Jiao XD, He X, Qin BD, Liu K, Wu Y, Liu J, Hou T, Zang YS. The prognostic value of tumor mutation burden in EGFR-mutant advanced lung adenocarcinoma, an analysis based on cBioPortal data base. J Thorac Dis 2019;11:4507-15. [PMID: 31903239 DOI: 10.21037/jtd.2019.11.04] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
60 Kim BJ, Jang HJ, Kim HS, Kim JH. Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers. J Cancer 2017;8:1460-5. [PMID: 28638461 DOI: 10.7150/jca.18470] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
61 Xu-Monette ZY, Zhang M, Li J, Young KH. PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response? Front Immunol. 2017;8:1597. [PMID: 29255458 DOI: 10.3389/fimmu.2017.01597] [Cited by in Crossref: 116] [Cited by in F6Publishing: 114] [Article Influence: 23.2] [Reference Citation Analysis]
62 Lin JH, Chen S, Pallavajjala A, Guedes LB, Lotan TL, Bacher JW, Eshleman JR. Validation of Long Mononucleotide Repeat Markers for Detection of Microsatellite Instability. J Mol Diagn 2021:S1525-1578(21)00420-7. [PMID: 34864149 DOI: 10.1016/j.jmoldx.2021.10.011] [Reference Citation Analysis]
63 Reilly NM, Novara L, Di Nicolantonio F, Bardelli A. Exploiting DNA repair defects in colorectal cancer. Mol Oncol. 2019;13:681-700. [PMID: 30714316 DOI: 10.1002/1878-0261.12467] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 11.3] [Reference Citation Analysis]
64 Zamarin D, Jazaeri AA. Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine. Gynecol Oncol 2016;141:86-94. [PMID: 27016233 DOI: 10.1016/j.ygyno.2015.12.030] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
65 Taylor ES, McCall JL, Girardin A, Munro FM, Black MA, Kemp RA. Functional impairment of infiltrating T cells in human colorectal cancer. Oncoimmunology. 2016;5:e1234573. [PMID: 27999752 DOI: 10.1080/2162402x.2016.1234573] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
66 Ghiringhelli F, Fumet JD. Is There a Place for Immunotherapy for Metastatic Microsatellite Stable Colorectal Cancer? Front Immunol 2019;10:1816. [PMID: 31447840 DOI: 10.3389/fimmu.2019.01816] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
67 Wang B, Li F, Zhou X, Ma Y, Fu W. Is microsatellite instability-high really a favorable prognostic factor for advanced colorectal cancer? A meta-analysis. World J Surg Oncol 2019;17:169. [PMID: 31639018 DOI: 10.1186/s12957-019-1706-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
68 Taube JM, Galon J, Sholl LM, Rodig SJ, Cottrell TR, Giraldo NA, Baras AS, Patel SS, Anders RA, Rimm DL, Cimino-Mathews A. Implications of the tumor immune microenvironment for staging and therapeutics. Mod Pathol 2018;31:214-34. [PMID: 29192647 DOI: 10.1038/modpathol.2017.156] [Cited by in Crossref: 136] [Cited by in F6Publishing: 138] [Article Influence: 27.2] [Reference Citation Analysis]
69 Chen S, Li X, Zhang J, Li L, Wang X, Zhu Y, Guo L, Wang J. Six mutator-derived lncRNA signature of genome instability for predicting the clinical outcome of colon cancer. J Gastrointest Oncol 2021;12:2157-71. [PMID: 34790382 DOI: 10.21037/jgo-21-494] [Reference Citation Analysis]
70 Acosta-Gonzalez G, Ouseph M, Lombardo K, Lu S, Glickman J, Resnick MB. Immune environment in serrated lesions of the colon: intraepithelial lymphocyte density, PD-1, and PD-L1 expression correlate with serrated neoplasia pathway progression. Hum Pathol. 2019;83:115-123. [PMID: 30172913 DOI: 10.1016/j.humpath.2018.08.020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
71 Liu SS, Yang YZ, Jiang C, Quan Q, Xie QK, Wang XP, He WZ, Rong YM, Chen P, Yang Q, Yang L, Zhang B, Xia XJ, Kong PF, Xia LP. Comparison of immunological characteristics between paired mismatch repair-proficient and -deficient colorectal cancer patients. J Transl Med 2018;16:195. [PMID: 30005666 DOI: 10.1186/s12967-018-1570-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
72 Wookey V, Grothey A. Update on the role of pembrolizumab in patients with unresectable or metastatic colorectal cancer. Therap Adv Gastroenterol 2021;14:17562848211024460. [PMID: 34262612 DOI: 10.1177/17562848211024460] [Reference Citation Analysis]
73 Mutala LB, Deleine C, Karakachoff M, Dansette D, Ducoin K, Oger R, Rousseau O, Podevin J, Duchalais E, Fourquier P, Thomas WEA, Gourraud PA, Bennouna J, Brochier C, Gervois N, Bossard C, Jarry A. The Caspase-1/IL-18 Axis of the Inflammasome in Tumor Cells: A Modulator of the Th1/Tc1 Response of Tumor-Infiltrating T Lymphocytes in Colorectal Cancer. Cancers (Basel) 2021;13:E189. [PMID: 33430344 DOI: 10.3390/cancers13020189] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Yang G, Zheng RY, Jin ZS. Correlations between microsatellite instability and the biological behaviour of tumours. J Cancer Res Clin Oncol 2019;145:2891-9. [PMID: 31617076 DOI: 10.1007/s00432-019-03053-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
75 Lee SJ, Jun SY, Lee IH, Kang BW, Park SY, Kim HJ, Park JS, Choi GS, Yoon G, Kim JG. CD274, LAG3, and IDO1 expressions in tumor-infiltrating immune cells as prognostic biomarker for patients with MSI-high colon cancer. J Cancer Res Clin Oncol 2018;144:1005-14. [PMID: 29520442 DOI: 10.1007/s00432-018-2620-x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 7.8] [Reference Citation Analysis]
76 Wang Z, Ran L, Chen C, Shi R, Dong Y, Li Y, Zhou X, Qi Y, Zhu P, Gao Y, Wu Y. Identification of HLA-A2-Restricted Mutant Epitopes from Neoantigens of Esophageal Squamous Cell Carcinoma. Vaccines (Basel) 2021;9:1118. [PMID: 34696226 DOI: 10.3390/vaccines9101118] [Reference Citation Analysis]
77 Meireson A, Devos M, Brochez L. IDO Expression in Cancer: Different Compartment, Different Functionality? Front Immunol 2020;11:531491. [PMID: 33072086 DOI: 10.3389/fimmu.2020.531491] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
78 Koganemaru S, Inoshita N, Miura Y, Miyama Y, Fukui Y, Ozaki Y, Tomizawa K, Hanaoka Y, Toda S, Suyama K, Tanabe Y, Moriyama J, Fujii T, Matoba S, Kuroyanagi H, Takano T. Prognostic value of programmed death-ligand 1 expression in patients with stage III colorectal cancer. Cancer Sci 2017;108:853-8. [PMID: 28267224 DOI: 10.1111/cas.13229] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 5.6] [Reference Citation Analysis]
79 Dmello RS, To SQ, Chand AL. Therapeutic Targeting of the Tumour Microenvironment in Metastatic Colorectal Cancer. Int J Mol Sci 2021;22:2067. [PMID: 33669775 DOI: 10.3390/ijms22042067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Copija A, Waniczek D, Witkoś A, Walkiewicz K, Nowakowska-Zajdel E. Clinical Significance and Prognostic Relevance of Microsatellite Instability in Sporadic Colorectal Cancer Patients. Int J Mol Sci 2017;18:E107. [PMID: 28067827 DOI: 10.3390/ijms18010107] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 8.0] [Reference Citation Analysis]
81 Huynh JC, Schwab E, Ji J, Kim E, Joseph A, Hendifar A, Cho M, Gong J. Recent Advances in Targeted Therapies for Advanced Gastrointestinal Malignancies. Cancers (Basel). 2020;12. [PMID: 32384640 DOI: 10.3390/cancers12051168] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
82 Gbolahan O, O'Neil B. Update on systemic therapy for colorectal cancer: biologics take sides. Transl Gastroenterol Hepatol 2019;4:9. [PMID: 30976712 DOI: 10.21037/tgh.2019.01.12] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
83 Kim S, Park S, Cho MS, Lim W, Moon BI, Sung SH. Strong Correlation of Indoleamine 2,3-Dioxygenase 1 Expression with Basal-Like Phenotype and Increased Lymphocytic Infiltration in Triple-Negative Breast Cancer. J Cancer. 2017;8:124-130. [PMID: 28123606 DOI: 10.7150/jca.17437] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
84 Otoshi T, Nagano T, Tachihara M, Nishimura Y. Possible Biomarkers for Cancer Immunotherapy. Cancers (Basel) 2019;11:E935. [PMID: 31277279 DOI: 10.3390/cancers11070935] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
85 Gonzalez-Exposito R, Semiannikova M, Griffiths B, Khan K, Barber LJ, Woolston A, Spain G, von Loga K, Challoner B, Patel R, Ranes M, Swain A, Thomas J, Bryant A, Saffery C, Fotiadis N, Guettler S, Mansfield D, Melcher A, Powles T, Rao S, Watkins D, Chau I, Matthews N, Wallberg F, Starling N, Cunningham D, Gerlinger M. CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids. J Immunother Cancer 2019;7:101. [PMID: 30982469 DOI: 10.1186/s40425-019-0575-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
86 Hamada T, Keum N, Nishihara R, Ogino S. Molecular pathological epidemiology: new developing frontiers of big data science to study etiologies and pathogenesis. J Gastroenterol. 2017;52:265-275. [PMID: 27738762 DOI: 10.1007/s00535-016-1272-3] [Cited by in Crossref: 65] [Cited by in F6Publishing: 67] [Article Influence: 10.8] [Reference Citation Analysis]
87 Singh PP, Sharma PK, Krishnan G, Lockhart AC. Immune checkpoints and immunotherapy for colorectal cancer. Gastroenterol Rep (Oxf). 2015;3:289-297. [PMID: 26510455 DOI: 10.1093/gastro/gov053] [Cited by in Crossref: 20] [Cited by in F6Publishing: 43] [Article Influence: 2.9] [Reference Citation Analysis]
88 Shin SJ, Kim SY, Choi YY, Son T, Cheong JH, Hyung WJ, Noh SH, Park CG, Kim HI. Mismatch Repair Status of Gastric Cancer and Its Association with the Local and Systemic Immune Response.Oncologist. 2019;24:e835-e844. [PMID: 30894409 DOI: 10.1634/theoncologist.2018-0273] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
89 Shevtsov M, Sato H, Multhoff G, Shibata A. Novel Approaches to Improve the Efficacy of Immuno-Radiotherapy. Front Oncol 2019;9:156. [PMID: 30941308 DOI: 10.3389/fonc.2019.00156] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 16.0] [Reference Citation Analysis]
90 Tong M, Wang J, He W, Wang Y, Pan H, Li D, Zhang H. Predictive biomarkers for tumor immune checkpoint blockade. Cancer Manag Res 2018;10:4501-7. [PMID: 30349382 DOI: 10.2147/CMAR.S179680] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
91 Wu S, Shi X, Wang J, Wang X, Liu Y, Luo Y, Mao F, Zeng X. Triple-Negative Breast Cancer: Intact Mismatch Repair and Partial Co-Expression of PD-L1 and LAG-3. Front Immunol 2021;12:561793. [PMID: 33717059 DOI: 10.3389/fimmu.2021.561793] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
92 Zhang J, Quadri S, Wolfgang CL, Zheng L. New Development of Biomarkers for Gastrointestinal Cancers: From Neoplastic Cells to Tumor Microenvironment. Biomedicines 2018;6:E87. [PMID: 30104497 DOI: 10.3390/biomedicines6030087] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
93 Fu T, Liu Y, Li K, Wan W, Pappou EP, Iacobuzio-Donahue CA, Kerner Z, Baylin SB, Wolfgang CL, Ahuja N. Tumors with unmethylated MLH1 and the CpG island methylator phenotype are associated with a poor prognosis in stage II colorectal cancer patients. Oncotarget 2016;7:86480-9. [PMID: 27880934 DOI: 10.18632/oncotarget.13441] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
94 Dutta R, Khalil R, Mayilsamy K, Green R, Howell M, Bharadwaj S, Mohapatra SS, Mohapatra S. Combination Therapy of Mithramycin A and Immune Checkpoint Inhibitor for the Treatment of Colorectal Cancer in an Orthotopic Murine Model. Front Immunol 2021;12:706133. [PMID: 34381456 DOI: 10.3389/fimmu.2021.706133] [Reference Citation Analysis]
95 Mileo AM, Nisticò P, Miccadei S. Polyphenols: Immunomodulatory and Therapeutic Implication in Colorectal Cancer. Front Immunol 2019;10:729. [PMID: 31031748 DOI: 10.3389/fimmu.2019.00729] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 14.3] [Reference Citation Analysis]
96 Kalyan A, Kircher S, Shah H, Mulcahy M, Benson A. Updates on immunotherapy for colorectal cancer. J Gastrointest Oncol 2018;9:160-9. [PMID: 29564182 DOI: 10.21037/jgo.2018.01.17] [Cited by in Crossref: 76] [Cited by in F6Publishing: 71] [Article Influence: 19.0] [Reference Citation Analysis]
97 Lee JB, Ha SJ, Kim HR. Clinical Insights Into Novel Immune Checkpoint Inhibitors. Front Pharmacol 2021;12:681320. [PMID: 34025438 DOI: 10.3389/fphar.2021.681320] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
98 Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL. Pembrolizumab (Keytruda). Hum Vaccin Immunother 2016;12:2777-89. [PMID: 27398650 DOI: 10.1080/21645515.2016.1199310] [Cited by in Crossref: 70] [Cited by in F6Publishing: 72] [Article Influence: 11.7] [Reference Citation Analysis]
99 Housseau F, Llosa NJ. Immune checkpoint blockade in microsatellite instable colorectal cancers: Back to the clinic. Oncoimmunology 2015;4:e1008858. [PMID: 26155426 DOI: 10.1080/2162402X.2015.1008858] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
100 Lee JJ, Chu E. Recent Advances in the Clinical Development of Immune Checkpoint Blockade Therapy for Mismatch Repair Proficient (pMMR)/non-MSI-H Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2018;17:258-273. [PMID: 30072278 DOI: 10.1016/j.clcc.2018.06.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
101 王维嘉, 王丹, 秦国慧, 陈新峰, 张毅. 免疫检查点抑制剂在结直肠癌中的应用以及未来发展方向. 世界华人消化杂志 2017; 25(19): 1714-1727 [DOI: 10.11569/wcjd.v25.i19.1714] [Reference Citation Analysis]
102 Deng D, Luo X, Zhang S, Xu Z. Immune cell infiltration-associated signature in colon cancer and its prognostic implications. Aging (Albany NY) 2021;13:19696-709. [PMID: 34349038 DOI: 10.18632/aging.203380] [Reference Citation Analysis]
103 Li J, Zhang Y, Xu Q, Wang G, Jiang L, Wei Q, Luo C, Chen L, Ying J. Systemic Inflammatory Markers of Resectable Colorectal Cancer Patients with Different Mismatch Repair Gene Status. Cancer Manag Res 2021;13:2925-35. [PMID: 33833576 DOI: 10.2147/CMAR.S298885] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
104 Horton BL, Fessenden TB, Spranger S. Tissue Site and the Cancer Immunity Cycle. Trends Cancer. 2019;5:593-603. [PMID: 31706507 DOI: 10.1016/j.trecan.2019.07.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
105 Matsumoto T, Okayama H, Nakajima S, Saito K, Nakano H, Endo E, Kase K, Ito M, Yamauchi N, Yamada L, Kanke Y, Onozawa H, Fujita S, Sakamoto W, Saito M, Saze Z, Momma T, Mimura K, Kono K. Tn Antigen Expression Defines an Immune Cold Subset of Mismatch-Repair Deficient Colorectal Cancer. Int J Mol Sci 2020;21:E9081. [PMID: 33260328 DOI: 10.3390/ijms21239081] [Reference Citation Analysis]
106 Yassin M, Sadowska Z, Djurhuus D, Nielsen B, Tougaard P, Olsen J, Pedersen AE. Upregulation of PD-1 follows tumour development in the AOM/DSS model of inflammation-induced colorectal cancer in mice. Immunology 2019;158:35-46. [PMID: 31429085 DOI: 10.1111/imm.13093] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
107 Klement JD, Poschel DB, Lu C, Merting AD, Yang D, Redd PS, Liu K. Osteopontin Blockade Immunotherapy Increases Cytotoxic T Lymphocyte Lytic Activity and Suppresses Colon Tumor Progression. Cancers (Basel) 2021;13:1006. [PMID: 33670921 DOI: 10.3390/cancers13051006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
108 Mowat C, Mosley SR, Namdar A, Schiller D, Baker K. Anti-tumor immunity in mismatch repair-deficient colorectal cancers requires type I IFN-driven CCL5 and CXCL10. J Exp Med 2021;218:e20210108. [PMID: 34297038 DOI: 10.1084/jem.20210108] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
109 Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372:2509-2520. [PMID: 26028255 DOI: 10.1056/nejmoa1500596] [Cited by in Crossref: 4650] [Cited by in F6Publishing: 2768] [Article Influence: 664.3] [Reference Citation Analysis]
110 Li X, Wen D, Li X, Yao C, Chong W, Chen H. Identification of an Immune Signature Predicting Prognosis Risk and Lymphocyte Infiltration in Colon Cancer. Front Immunol 2020;11:1678. [PMID: 33013820 DOI: 10.3389/fimmu.2020.01678] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
111 Fantini MC, Favale A, Onali S, Facciotti F. Tumor Infiltrating Regulatory T Cells in Sporadic and Colitis-Associated Colorectal Cancer: The Red Little Riding Hood and the Wolf. Int J Mol Sci 2020;21:E6744. [PMID: 32937953 DOI: 10.3390/ijms21186744] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
112 Zhao X, May A, Lou E, Subramanian S. Genotypic and phenotypic signatures to predict immune checkpoint blockade therapy response in patients with colorectal cancer. Transl Res 2018;196:62-70. [PMID: 29518351 DOI: 10.1016/j.trsl.2018.02.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
113 Carethers JM, Jung BH. Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer. Gastroenterology 2015; 149: 1177-1190. e3. [PMID: 26216840 DOI: 10.1053/j.gastro.2015.06.047] [Cited by in Crossref: 198] [Cited by in F6Publishing: 195] [Article Influence: 28.3] [Reference Citation Analysis]
114 Park R, Winnicki M, Liu E, Chu WM. Immune checkpoints and cancer in the immunogenomics era. Brief Funct Genomics 2019;18:133-9. [PMID: 30137232 DOI: 10.1093/bfgp/ely027] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
115 Thelen M, Wennhold K, Lehmann J, Garcia-Marquez M, Klein S, Kochen E, Lohneis P, Lechner A, Wagener-Ryczek S, Plum PS, Velazquez Camacho O, Pfister D, Dörr F, Heldwein M, Hekmat K, Beutner D, Klussmann JP, Thangarajah F, Ratiu D, Malter W, Merkelbach-Bruse S, Bruns CJ, Quaas A, von Bergwelt-Baildon M, Schlößer HA. Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy. NPJ Precis Oncol 2021;5:52. [PMID: 34135436 DOI: 10.1038/s41698-021-00196-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
116 Ugai T, Zhao M, Shimizu T, Akimoto N, Shi S, Takashima Y, Zhong R, Lau MC, Haruki K, Arima K, Fujiyoshi K, Langworthy B, Masugi Y, da Silva A, Nosho K, Baba Y, Song M, Chan AT, Wang M, Meyerhardt JA, Giannakis M, Väyrynen JP, Nowak JA, Ogino S. Association of PIK3CA mutation and PTEN loss with expression of CD274 (PD-L1) in colorectal carcinoma. Oncoimmunology 2021;10:1956173. [PMID: 34377593 DOI: 10.1080/2162402X.2021.1956173] [Reference Citation Analysis]
117 Zhang Y, Sun Z, Mao X, Wu H, Luo F, Wu X, Zhou L, Qin J, Zhao L, Bai C. Impact of mismatch-repair deficiency on the colorectal cancer immune microenvironment. Oncotarget 2017;8:85526-36. [PMID: 29156738 DOI: 10.18632/oncotarget.20241] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
118 Kokolus KM, Obermajer N, Kalinski P. Quantitative evaluation of tumor-specific T cells in tumors and lymphoid tissues. Methods Enzymol 2020;635:149-66. [PMID: 32122543 DOI: 10.1016/bs.mie.2019.05.041] [Reference Citation Analysis]
119 Shen R, Li P, Li B, Zhang B, Feng L, Cheng S. Identification of Distinct Immune Subtypes in Colorectal Cancer Based on the Stromal Compartment. Front Oncol 2019;9:1497. [PMID: 31998649 DOI: 10.3389/fonc.2019.01497] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
120 Sanz-Pamplona R, Gil-Hoyos R, López-Doriga A, Alonso MH, Aussó S, Molleví DG, Santos C, Sanjuán X, Salazar R, Alemany R, Moreno V. Mutanome and expression of immune response genes in microsatellite stable colon cancer. Oncotarget 2016;7:17711-25. [PMID: 26871478 DOI: 10.18632/oncotarget.7293] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
121 Myint ZW, Goel G. Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress. J Hematol Oncol. 2017;10:86. [PMID: 28434400 DOI: 10.1186/s13045-017-0454-7] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 8.8] [Reference Citation Analysis]
122 Mani NL, Schalper KA, Hatzis C, Saglam O, Tavassoli F, Butler M, Chagpar AB, Pusztai L, Rimm DL. Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer. Breast Cancer Res 2016;18:78. [PMID: 27473061 DOI: 10.1186/s13058-016-0737-x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 7.0] [Reference Citation Analysis]
123 Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, Shia J, Segal NH, Diaz LA Jr. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol 2019;16:361-75. [PMID: 30886395 DOI: 10.1038/s41575-019-0126-x] [Cited by in Crossref: 241] [Cited by in F6Publishing: 245] [Article Influence: 80.3] [Reference Citation Analysis]
124 Cao Y, Nishihara R, Qian ZR, Song M, Mima K, Inamura K, Nowak JA, Drew DA, Lochhead P, Nosho K. Regular Aspirin Use Associates With Lower Risk of Colorectal Cancers With Low Numbers of Tumor-Infiltrating Lymphocytes. Gastroenterology. 2016;151:879-892.e4. [PMID: 27475305 DOI: 10.1053/j.gastro.2016.07.030] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 6.5] [Reference Citation Analysis]
125 Ahmed M. Colon Cancer: A Clinician's Perspective in 2019. Gastroenterology Res 2020;13:1-10. [PMID: 32095167 DOI: 10.14740/gr1239] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 18.5] [Reference Citation Analysis]
126 Shi R, Li Y, Ran L, Dong Y, Zhou X, Tang J, Han L, Wang M, Pang L, Qi Y, Wu Y, Gao Y. Screening and identification of HLA-A2-restricted neoepitopes for immunotherapy of non-microsatellite instability-high colorectal cancer. Sci China Life Sci 2021. [PMID: 34236583 DOI: 10.1007/s11427-021-1944-5] [Reference Citation Analysis]
127 Kawazoe A, Shitara K, Kuboki Y, Bando H, Kojima T, Yoshino T, Ohtsu A, Ochiai A, Togashi Y, Nishikawa H, Doi T, Kuwata T. Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer. Gastric Cancer. 2019;22:69-76. [PMID: 29859006 DOI: 10.1007/s10120-018-0843-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
128 Li L, Rao X, Wen Z, Ding X, Wang X, Xu W, Meng C, Yi Y, Guan Y, Chen Y, Wang J, Jun L. Implications of driver genes associated with a high tumor mutation burden identified using next-generation sequencing on immunotherapy in hepatocellular carcinoma. Oncol Lett 2020;19:2739-48. [PMID: 32218826 DOI: 10.3892/ol.2020.11372] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
129 Mager LF, Wasmer MH, Rau TT, Krebs P. Cytokine-Induced Modulation of Colorectal Cancer. Front Oncol. 2016;6:96. [PMID: 27148488 DOI: 10.3389/fonc.2016.00096] [Cited by in Crossref: 102] [Cited by in F6Publishing: 102] [Article Influence: 17.0] [Reference Citation Analysis]
130 Cohen R, Rousseau B, Vidal J, Colle R, Diaz LA Jr, André T. Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond. Target Oncol 2020;15:11-24. [PMID: 31786718 DOI: 10.1007/s11523-019-00690-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 14.0] [Reference Citation Analysis]
131 Razi A, Afghah F, Singh S, Varadan V. Network-Based Enriched Gene Subnetwork Identification: A Game-Theoretic Approach. Biomed Eng Comput Biol 2016;7:1-14. [PMID: 27081328 DOI: 10.4137/BECB.S38244] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
132 Zhang L, Zhao Y, Dai Y, Cheng JN, Gong Z, Feng Y, Sun C, Jia Q, Zhu B. Immune Landscape of Colorectal Cancer Tumor Microenvironment from Different Primary Tumor Location. Front Immunol 2018;9:1578. [PMID: 30042763 DOI: 10.3389/fimmu.2018.01578] [Cited by in Crossref: 61] [Cited by in F6Publishing: 63] [Article Influence: 15.3] [Reference Citation Analysis]
133 He R, Lao Y, Yu W, Zhang X, Jiang M, Zhu C. Progress in the Application of Immune Checkpoint Inhibitor-Based Immunotherapy for Targeting Different Types of Colorectal Cancer. Front Oncol 2021;11:764618. [PMID: 34888243 DOI: 10.3389/fonc.2021.764618] [Reference Citation Analysis]
134 Shan C, Li X, Zhang J. Progress of immune checkpoint LAG-3 in immunotherapy. Oncol Lett 2020;20:207. [PMID: 32963613 DOI: 10.3892/ol.2020.12070] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
135 Bhatt D, Kang B, Sawant D, Zheng L, Perez K, Huang Z, Sekirov L, Wolak D, Huang JY, Liu X, DeVoss J, Manzanillo PS, Pierce N, Zhang Z, Symons A, Ouyang W. STARTRAC analyses of scRNAseq data from tumor models reveal T cell dynamics and therapeutic targets. J Exp Med 2021;218:e20201329. [PMID: 33900375 DOI: 10.1084/jem.20201329] [Reference Citation Analysis]
136 Ishii T, Kawazoe A, Shitara K. Dawn of precision medicine on gastric cancer. Int J Clin Oncol 2019;24:779-88. [PMID: 30976939 DOI: 10.1007/s10147-019-01441-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
137 Qin T, Cui XY, Xiu H, Huang C, Sun ZN, Xu XM, Li LH, Yue L. USP37 downregulation elevates the Chemical Sensitivity of Human Breast Cancer Cells to Adriamycin. Int J Med Sci 2021;18:325-34. [PMID: 33390801 DOI: 10.7150/ijms.54301] [Reference Citation Analysis]
138 Johnson BA 3rd, Yarchoan M, Lee V, Laheru DA, Jaffee EM. Strategies for Increasing Pancreatic Tumor Immunogenicity. Clin Cancer Res. 2017;23:1656-1669. [PMID: 28373364 DOI: 10.1158/1078-0432.ccr-16-2318] [Cited by in Crossref: 68] [Cited by in F6Publishing: 45] [Article Influence: 17.0] [Reference Citation Analysis]
139 Pakish JB, Zhang Q, Chen Z, Liang H, Chisholm GB, Yuan Y, Mok SC, Broaddus RR, Lu KH, Yates MS. Immune Microenvironment in Microsatellite-Instable Endometrial Cancers: Hereditary or Sporadic Origin Matters. Clin Cancer Res 2017;23:4473-81. [PMID: 28264871 DOI: 10.1158/1078-0432.CCR-16-2655] [Cited by in Crossref: 44] [Cited by in F6Publishing: 32] [Article Influence: 8.8] [Reference Citation Analysis]
140 Lee LH, Cavalcanti MS, Segal NH, Hechtman JF, Weiser MR, Smith JJ, Garcia-Aguilar J, Sadot E, Ntiamoah P, Markowitz AJ, Shike M, Stadler ZK, Vakiani E, Klimstra DS, Shia J. Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma. Mod Pathol. 2016;29:1433-1442. [PMID: 27443512 DOI: 10.1038/modpathol.2016.139] [Cited by in Crossref: 85] [Cited by in F6Publishing: 90] [Article Influence: 14.2] [Reference Citation Analysis]
141 Vasaikar S, Huang C, Wang X, Petyuk VA, Savage SR, Wen B, Dou Y, Zhang Y, Shi Z, Arshad OA, Gritsenko MA, Zimmerman LJ, McDermott JE, Clauss TR, Moore RJ, Zhao R, Monroe ME, Wang YT, Chambers MC, Slebos RJC, Lau KS, Mo Q, Ding L, Ellis M, Thiagarajan M, Kinsinger CR, Rodriguez H, Smith RD, Rodland KD, Liebler DC, Liu T, Zhang B; Clinical Proteomic Tumor Analysis Consortium. Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities. Cell 2019;177:1035-1049.e19. [PMID: 31031003 DOI: 10.1016/j.cell.2019.03.030] [Cited by in Crossref: 167] [Cited by in F6Publishing: 154] [Article Influence: 55.7] [Reference Citation Analysis]
142 Xu L, Pelosof L, Wang R, McFarland HI, Wu WW, Phue JN, Lee CT, Shen RF, Juhl H, Wu LH, Alterovitz WL, Petricon E, Rosenberg AS. NGS Evaluation of Colorectal Cancer Reveals Interferon Gamma Dependent Expression of Immune Checkpoint Genes and Identification of Novel IFNγ Induced Genes. Front Immunol 2020;11:224. [PMID: 32265897 DOI: 10.3389/fimmu.2020.00224] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
143 Tian H, Shi G, Wang Q, Li Y, Yang Q, Li C, Yang G, Wu M, Xie Q, Zhang S, Yang Y, Xiang R, Yu D, Wei Y, Deng H. A novel cancer vaccine with the ability to simultaneously produce anti-PD-1 antibody and GM-CSF in cancer cells and enhance Th1-biased antitumor immunity. Signal Transduct Target Ther 2016;1:16025. [PMID: 29263903 DOI: 10.1038/sigtrans.2016.25] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
144 Liu JY, Peng CW, Yang GF, Hu WQ, Yang XJ, Huang CQ, Xiong B, Li Y. Distribution pattern of tumor associated macrophages predicts the prognosis of gastric cancer. Oncotarget 2017;8:92757-69. [PMID: 29190953 DOI: 10.18632/oncotarget.21575] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
145 Tape CJ. The Heterocellular Emergence of Colorectal Cancer. Trends Cancer 2017;3:79-88. [PMID: 28239669 DOI: 10.1016/j.trecan.2016.12.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
146 Letai A. Functional precision cancer medicine-moving beyond pure genomics. Nat Med. 2017;23:1028-1035. [PMID: 28886003 DOI: 10.1038/nm.4389] [Cited by in Crossref: 145] [Cited by in F6Publishing: 119] [Article Influence: 29.0] [Reference Citation Analysis]
147 Levitzki A, Klein S. My journey from tyrosine phosphorylation inhibitors to targeted immune therapy as strategies to combat cancer. Proc Natl Acad Sci U S A 2019;116:11579-86. [PMID: 31076554 DOI: 10.1073/pnas.1816012116] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
148 Zumwalt TJ, Goel A. Immunotherapy of Metastatic Colorectal Cancer: Prevailing Challenges and New Perspectives. Curr Colorectal Cancer Rep. 2015;11:125-140. [PMID: 26441489 DOI: 10.1007/s11888-015-0269-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
149 Peng QH, Wang CH, Chen HM, Zhang RX, Pan ZZ, Lu ZH, Wang GY, Yue X, Huang W, Liu RY. CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer. J Immunother Cancer 2021;9:e001638. [PMID: 33579737 DOI: 10.1136/jitc-2020-001638] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
150 Varnier R, Garrivier T, Hafliger E, Favre A, Coutzac C, Spire C, Rochefort P, Sarabi M, Desseigne F, Guibert P, Cattey-Javouhey A, Funk-Debleds P, Mastier C, Buisson A, Pérol D, Trédan O, Blay JY, Phelip JM, de la Fouchardiere C. Hyperprogressive Disease After Combined Anti-PD-L1 and Anti-CTLA-4 Immunotherapy for MSI-H/dMMR Gastric Cancer: A Case Report. Front Oncol 2021;11:756365. [PMID: 34631593 DOI: 10.3389/fonc.2021.756365] [Reference Citation Analysis]
151 Lecocq Q, Keyaerts M, Devoogdt N, Breckpot K. The Next-Generation Immune Checkpoint LAG-3 and Its Therapeutic Potential in Oncology: Third Time's a Charm. Int J Mol Sci 2020;22:E75. [PMID: 33374804 DOI: 10.3390/ijms22010075] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
152 Beatty GL, O'Dwyer PJ, Clark J, Shi JG, Bowman KJ, Scherle PA, Newton RC, Schaub R, Maleski J, Leopold L, Gajewski TF. First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies. Clin Cancer Res 2017;23:3269-76. [PMID: 28053021 DOI: 10.1158/1078-0432.CCR-16-2272] [Cited by in Crossref: 164] [Cited by in F6Publishing: 99] [Article Influence: 32.8] [Reference Citation Analysis]
153 Yuza K, Nagahashi M, Watanabe S, Takabe K, Wakai T. Hypermutation and microsatellite instability in gastrointestinal cancers. Oncotarget 2017;8:112103-15. [PMID: 29340115 DOI: 10.18632/oncotarget.22783] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 7.4] [Reference Citation Analysis]
154 Azcue P, Encío I, Guerrero Setas D, Suarez Alecha J, Galbete A, Mercado M, Vera R, Gomez-Dorronsoro ML. PD-L1 as a Prognostic Factor in Early-Stage Colon Carcinoma within the Immunohistochemical Molecular Subtype Classification. Cancers (Basel) 2021;13:1943. [PMID: 33920689 DOI: 10.3390/cancers13081943] [Reference Citation Analysis]
155 Zhang J, Shih DJH, Lin SY. Role of DNA repair defects in predicting immunotherapy response. Biomark Res 2020;8:23. [PMID: 32612833 DOI: 10.1186/s40364-020-00202-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
156 He WZ, Hu WM, Kong PF, Yang L, Yang YZ, Xie QK, Jiang C, Yin CX, Qiu HJ, Zhang B, Zhang HZ, Xia LP. Systemic neutrophil lymphocyte ratio and mismatch repair status in colorectal cancer patients: correlation and prognostic value. J Cancer 2018;9:3093-100. [PMID: 30210632 DOI: 10.7150/jca.26669] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
157 Ruiz-Bañobre J, Goel A. DNA Mismatch Repair Deficiency and Immune Checkpoint Inhibitors in Gastrointestinal Cancers. Gastroenterology 2019;156:890-903. [PMID: 30578781 DOI: 10.1053/j.gastro.2018.11.071] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
158 Chapuy B, Stewart C, Dunford AJ, Kim J, Wienand K, Kamburov A, Griffin GK, Chen PH, Lako A, Redd RA, Cote CM, Ducar MD, Thorner AR, Rodig SJ, Getz G, Shipp MA. Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade. Blood 2019;134:2369-82. [PMID: 31697821 DOI: 10.1182/blood.2019002067] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 12.0] [Reference Citation Analysis]
159 Wang Y, Dong J, Quan Q, Liu S, Chen X, Cai X, Qiu H, Zhang B, Guo G. Immune Cell Infiltration of the Primary Tumor Microenvironment Predicted the Treatment Outcome of Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients. Front Oncol 2020;10:581051. [PMID: 33585196 DOI: 10.3389/fonc.2020.581051] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
160 Martini G, Dienstmann R, Ros J, Baraibar I, Cuadra-Urteaga JL, Salva F, Ciardiello D, Mulet N, Argiles G, Tabernero J, Elez E. Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer. Ther Adv Med Oncol 2020;12:1758835920936089. [PMID: 32782486 DOI: 10.1177/1758835920936089] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
161 Song W, Ren J, Xiang R, Kong C, Fu T. Identification of pyroptosis-related subtypes, the development of a prognosis model, and characterization of tumor microenvironment infiltration in colorectal cancer. Oncoimmunology 2021;10:1987636. [PMID: 34676149 DOI: 10.1080/2162402X.2021.1987636] [Reference Citation Analysis]
162 Havel JJ, Chan TA. High-resolution genomic analysis: the tumor-immune interface comes into focus. Genome Biol 2015;16:65. [PMID: 25853850 DOI: 10.1186/s13059-015-0631-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
163 Liang F, Rezapour A, Szeponik L, Alsén S, Wettergren Y, Bexe Lindskog E, Quiding-Järbrink M, Yrlid U. Antigen Presenting Cells from Tumor and Colon of Colorectal Cancer Patients Are Distinct in Activation and Functional Status, but Comparably Responsive to Activated T Cells. Cancers (Basel) 2021;13:5247. [PMID: 34680397 DOI: 10.3390/cancers13205247] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
164 Xu B, Lu M, Yan L, Ge M, Ren Y, Wang R, Shu Y, Hou L, Guo H. A Pan-Cancer Analysis of Predictive Methylation Signatures of Response to Cancer Immunotherapy. Front Immunol 2021;12:796647. [PMID: 34956232 DOI: 10.3389/fimmu.2021.796647] [Reference Citation Analysis]
165 Berthenet K, Boudesco C, Collura A, Svrcek M, Richaud S, Hammann A, Causse S, Yousfi N, Wanherdrick K, Duplomb L, Duval A, Garrido C, Jego G. Extracellular HSP110 skews macrophage polarization in colorectal cancer. Oncoimmunology 2016;5:e1170264. [PMID: 27622020 DOI: 10.1080/2162402X.2016.1170264] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
166 Lee JL, Roh SA, Kim CW, Kwon YH, Ha YJ, Kim SK, Kim SY, Cho DH, Kim YS, Kim JC. Clinical assessment and identification of immuno-oncology markers concerning the 19-gene based risk classifier in stage IV colorectal cancer. World J Gastroenterol 2019; 25(11): 1341-1354 [PMID: 30918427 DOI: 10.3748/wjg.v25.i11.1341] [Reference Citation Analysis]
167 He X, Wu K, Ogino S, Giovannucci EL, Chan AT, Song M. Association Between Risk Factors for Colorectal Cancer and Risk of Serrated Polyps and Conventional Adenomas. Gastroenterology. 2018;155:355-373.e18. [PMID: 29702117 DOI: 10.1053/j.gastro.2018.04.019] [Cited by in Crossref: 63] [Cited by in F6Publishing: 60] [Article Influence: 15.8] [Reference Citation Analysis]
168 Ferrarese R, Zuppardo RA, Puzzono M, Mannucci A, Amato V, Ditonno I, Patricelli MG, Raucci AR, Clementi M, Elmore U, Rosati R, Testoni PA, Mancini N, Cavestro GM. Oral and Fecal Microbiota in Lynch Syndrome. J Clin Med 2020;9:E2735. [PMID: 32847083 DOI: 10.3390/jcm9092735] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
169 Puhr HC, Ilhan-Mutlu A. New emerging targets in cancer immunotherapy: the role of LAG3. ESMO Open 2019;4:e000482. [PMID: 31231559 DOI: 10.1136/esmoopen-2018-000482] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 10.0] [Reference Citation Analysis]
170 Llosa NJ, Luber B, Siegel N, Awan AH, Oke T, Zhu Q, Bartlett BR, Aulakh LK, Thompson ED, Jaffee EM, Durham JN, Sears CL, Le DT, Diaz LA Jr, Pardoll DM, Wang H, Housseau F, Anders RA. Immunopathologic Stratification of Colorectal Cancer for Checkpoint Blockade Immunotherapy. Cancer Immunol Res 2019;7:1574-9. [PMID: 31439614 DOI: 10.1158/2326-6066.CIR-18-0927] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
171 Bui QL, Mas L, Hollebecque A, Tougeron D, de la Fouchardière C, Pudlarz T, Alouani E, Guimbaud R, Taieb J, André T, Colle R, Cohen R. Treatments after Immune Checkpoint Inhibitors in Patients with dMMR/MSI Metastatic Colorectal Cancer. Cancers 2022;14:406. [DOI: 10.3390/cancers14020406] [Reference Citation Analysis]
172 Frankell AM, Jammula S, Li X, Contino G, Killcoyne S, Abbas S, Perner J, Bower L, Devonshire G, Ococks E, Grehan N, Mok J, O'Donovan M, MacRae S, Eldridge MD, Tavaré S, Fitzgerald RC; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium. The landscape of selection in 551 esophageal adenocarcinomas defines genomic biomarkers for the clinic. Nat Genet 2019;51:506-16. [PMID: 30718927 DOI: 10.1038/s41588-018-0331-5] [Cited by in Crossref: 70] [Cited by in F6Publishing: 64] [Article Influence: 23.3] [Reference Citation Analysis]
173 Sinicrope FA, Okamoto K, Kasi PM, Kawakami H. Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer. Clin Gastroenterol Hepatol. 2016;14:651-658. [PMID: 26872400 DOI: 10.1016/j.cgh.2016.02.008] [Cited by in Crossref: 62] [Cited by in F6Publishing: 68] [Article Influence: 10.3] [Reference Citation Analysis]
174 Sveen A, Kopetz S, Lothe RA. Biomarker-guided therapy for colorectal cancer: strength in complexity. Nat Rev Clin Oncol 2020;17:11-32. [PMID: 31289352 DOI: 10.1038/s41571-019-0241-1] [Cited by in Crossref: 67] [Cited by in F6Publishing: 68] [Article Influence: 22.3] [Reference Citation Analysis]
175 Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, Bot BM, Morris JS, Simon IM, Gerster S, Fessler E, De Sousa E Melo F, Missiaglia E, Ramay H, Barras D, Homicsko K, Maru D, Manyam GC, Broom B, Boige V, Perez-Villamil B, Laderas T, Salazar R, Gray JW, Hanahan D, Tabernero J, Bernards R, Friend SH, Laurent-Puig P, Medema JP, Sadanandam A, Wessels L, Delorenzi M, Kopetz S, Vermeulen L, Tejpar S. The consensus molecular subtypes of colorectal cancer. Nat Med 2015;21:1350-6. [PMID: 26457759 DOI: 10.1038/nm.3967] [Cited by in Crossref: 1929] [Cited by in F6Publishing: 1762] [Article Influence: 275.6] [Reference Citation Analysis]
176 He Y, Liu ZX, Jiang ZH, Wang XS. Identification of genomic features associated with immunotherapy response in gastrointestinal cancers. World J Gastrointest Oncol 2019; 11(4): 270-280 [PMID: 31040893 DOI: 10.4251/wjgo.v11.i4.270] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
177 de Vries NL, Swets M, Vahrmeijer AL, Hokland M, Kuppen PJ. The Immunogenicity of Colorectal Cancer in Relation to Tumor Development and Treatment. Int J Mol Sci 2016;17:E1030. [PMID: 27367680 DOI: 10.3390/ijms17071030] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
178 Lin EI, Tseng LH, Gocke CD, Reil S, Le DT, Azad NS, Eshleman JR. Mutational profiling of colorectal cancers with microsatellite instability. Oncotarget 2015;6:42334-44. [PMID: 26517354 DOI: 10.18632/oncotarget.5997] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 7.0] [Reference Citation Analysis]
179 Kawazoe A, Kuwata T, Kuboki Y, Shitara K, Nagatsuma AK, Aizawa M, Yoshino T, Doi T, Ohtsu A, Ochiai A. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients. Gastric Cancer. 2017;20:407-415. [PMID: 27629881 DOI: 10.1007/s10120-016-0631-3] [Cited by in Crossref: 93] [Cited by in F6Publishing: 101] [Article Influence: 15.5] [Reference Citation Analysis]
180 Griffiths JI, Wallet P, Pflieger LT, Stenehjem D, Liu X, Cosgrove PA, Leggett NA, McQuerry JA, Shrestha G, Rossetti M, Sunga G, Moos PJ, Adler FR, Chang JT, Sharma S, Bild AH. Circulating immune cell phenotype dynamics reflect the strength of tumor-immune cell interactions in patients during immunotherapy. Proc Natl Acad Sci U S A 2020;117:16072-82. [PMID: 32571915 DOI: 10.1073/pnas.1918937117] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
181 Byrne M, Saif MW. Selecting treatment options in refractory metastatic colorectal cancer. Onco Targets Ther 2019;12:2271-8. [PMID: 30988631 DOI: 10.2147/OTT.S194605] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
182 Rosenbaum MW, Gigliotti BJ, Pai SI, Parangi S, Wachtel H, Mino-Kenudson M, Gunda V, Faquin WC. PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma. Endocr Pathol 2018;29:59-67. [PMID: 29372535 DOI: 10.1007/s12022-018-9514-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
183 Masugi Y, Nishihara R, Yang J, Mima K, da Silva A, Shi Y, Inamura K, Cao Y, Song M, Nowak JA, Liao X, Nosho K, Chan AT, Giannakis M, Bass AJ, Hodi FS, Freeman GJ, Rodig S, Fuchs CS, Qian ZR, Ogino S. Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. Gut 2017;66:1463-73. [PMID: 27196573 DOI: 10.1136/gutjnl-2016-311421] [Cited by in Crossref: 94] [Cited by in F6Publishing: 97] [Article Influence: 15.7] [Reference Citation Analysis]
184 Chen G, Yang Z, Eshleman JR, Netto GJ, Lin MT. Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective. Biomed Res Int 2016;2016:9850690. [PMID: 27699178 DOI: 10.1155/2016/9850690] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
185 Bai R, Lv Z, Xu D, Cui J. Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors. Biomark Res 2020;8:34. [PMID: 32864131 DOI: 10.1186/s40364-020-00209-0] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 17.0] [Reference Citation Analysis]
186 Yu Y. Molecular classification and precision therapy of cancer: immune checkpoint inhibitors. Front Med. 2018;12:229-235. [PMID: 29209918 DOI: 10.1007/s11684-017-0581-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 5.6] [Reference Citation Analysis]
187 So YK, Byeon SJ, Ku BM, Ko YH, Ahn MJ, Son YI, Chung MK. An increase of CD8+ T cell infiltration following recurrence is a good prognosticator in HNSCC. Sci Rep 2020;10:20059. [PMID: 33208791 DOI: 10.1038/s41598-020-77036-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
188 Takahashi N, Iwasa S, Sasaki Y, Shoji H, Honma Y, Takashima A, Okita NT, Kato K, Hamaguchi T, Yamada Y. Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer. J Cancer Res Clin Oncol 2016;142:1727-38. [PMID: 27256004 DOI: 10.1007/s00432-016-2184-6] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 7.7] [Reference Citation Analysis]
189 Linette GP, Carreno BM. Tumor-Infiltrating Lymphocytes in the Checkpoint Inhibitor Era. Curr Hematol Malig Rep 2019;14:286-91. [PMID: 31187421 DOI: 10.1007/s11899-019-00523-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
190 Voutsadakis IA. Immune blockade inhibitors and the radiation abscopal effect in gastrointestinal cancers. World J Gastrointest Oncol 2018; 10(9): 221-227 [PMID: 30254717 DOI: 10.4251/wjgo.v10.i9.221] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
191 De Leo EK, Shah CP, Grajo JR, Liu X, Parekh H. Extramedullary Hematopoiesis in Mismatch Repair Deficient Colon Cancer Patient on Adjuvant Chemotherapy. Cureus 2021;13:e12899. [PMID: 33654584 DOI: 10.7759/cureus.12899] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
192 Mima K, Sukawa Y, Nishihara R, Qian ZR, Yamauchi M, Inamura K, Kim SA, Masuda A, Nowak JA, Nosho K, Kostic AD, Giannakis M, Watanabe H, Bullman S, Milner DA, Harris CC, Giovannucci E, Garraway LA, Freeman GJ, Dranoff G, Chan AT, Garrett WS, Huttenhower C, Fuchs CS, Ogino S. Fusobacterium nucleatum and T Cells in Colorectal Carcinoma. JAMA Oncol. 2015;1:653-661. [PMID: 26181352 DOI: 10.1001/jamaoncol.2015.13] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
193 Dong M, Meng Z, Kuerban K, Qi F, Liu J, Wei Y, Wang Q, Jiang S, Feng M, Ye L. Diosgenin promotes antitumor immunity and PD-1 antibody efficacy against melanoma by regulating intestinal microbiota. Cell Death Dis 2018;9:1039. [PMID: 30305604 DOI: 10.1038/s41419-018-1099-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
194 Li X, Song W, Shao C, Shi Y, Han W. Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy. Cell Mol Immunol 2019;16:28-39. [PMID: 30002451 DOI: 10.1038/s41423-018-0086-z] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]
195 Tauriello DV, Calon A, Lonardo E, Batlle E. Determinants of metastatic competency in colorectal cancer. Mol Oncol. 2017;11:97-119. [PMID: 28085225 DOI: 10.1002/1878-0261.12018] [Cited by in Crossref: 70] [Cited by in F6Publishing: 74] [Article Influence: 14.0] [Reference Citation Analysis]
196 Borcherding N, Kolb R, Gullicksrud J, Vikas P, Zhu Y, Zhang W. Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer. J Mol Biol 2018;430:2014-29. [PMID: 29800567 DOI: 10.1016/j.jmb.2018.05.030] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
197 Liang F, Rezapour A, Falk P, Angenete E, Yrlid U. Cryopreservation of Whole Tumor Biopsies from Rectal Cancer Patients Enable Phenotypic and In Vitro Functional Evaluation of Tumor-Infiltrating T Cells. Cancers (Basel) 2021;13:2428. [PMID: 34067849 DOI: 10.3390/cancers13102428] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
198 Jun SY, Lee EJ, Kim MJ, Chun SM, Bae YK, Hong SU, Choi J, Kim JM, Jang KT, Kim JY, Kim GI, Jung SJ, Yoon G, Hong SM. Lynch syndrome-related small intestinal adenocarcinomas. Oncotarget 2017;8:21483-500. [PMID: 28206961 DOI: 10.18632/oncotarget.15277] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
199 Zhang S, Bai W, Tong X, Bu P, Xu J, Xi Y. Correlation between tumor microenvironment-associated factors and the efficacy and prognosis of neoadjuvant therapy for rectal cancer. Oncol Lett 2019;17:1062-70. [PMID: 30655866 DOI: 10.3892/ol.2018.9682] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
200 Jiang M, Jia K, Wang L, Li W, Chen B, Liu Y, Wang H, Zhao S, He Y, Zhou C. Alterations of DNA damage repair in cancer: from mechanisms to applications. Ann Transl Med 2020;8:1685. [PMID: 33490197 DOI: 10.21037/atm-20-2920] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
201 Kim KJ, Yang HK, Kim WH, Kang GH. Combined prognostic effect of PD-L1 expression and immunoscore in microsatellite-unstable advanced gastric cancers. Oncotarget 2017;8:58887-902. [PMID: 28938605 DOI: 10.18632/oncotarget.19439] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
202 Kawakami H, Hironaka S, Esaki T, Chayama K, Tsuda M, Sugimoto N, Kadowaki S, Makiyama A, Machida N, Hirano H, Hirata K, Hara H, Yabusaki H, Komatsu Y, Muro K. An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7). Cancers (Basel) 2021;13:805. [PMID: 33671871 DOI: 10.3390/cancers13040805] [Reference Citation Analysis]
203 Chen B, Scurrah CR, McKinley ET, Simmons AJ, Ramirez-Solano MA, Zhu X, Markham NO, Heiser CN, Vega PN, Rolong A, Kim H, Sheng Q, Drewes JL, Zhou Y, Southard-Smith AN, Xu Y, Ro J, Jones AL, Revetta F, Berry LD, Niitsu H, Islam M, Pelka K, Hofree M, Chen JH, Sarkizova S, Ng K, Giannakis M, Boland GM, Aguirre AJ, Anderson AC, Rozenblatt-Rosen O, Regev A, Hacohen N, Kawasaki K, Sato T, Goettel JA, Grady WM, Zheng W, Washington MK, Cai Q, Sears CL, Goldenring JR, Franklin JL, Su T, Huh WJ, Vandekar S, Roland JT, Liu Q, Coffey RJ, Shrubsole MJ, Lau KS. Differential pre-malignant programs and microenvironment chart distinct paths to malignancy in human colorectal polyps. Cell 2021;184:6262-6280.e26. [PMID: 34910928 DOI: 10.1016/j.cell.2021.11.031] [Reference Citation Analysis]
204 Sanz-Pamplona R, Melas M, Maoz A, Schmit SL, Rennert H, Lejbkowicz F, Greenson JK, Sanjuan X, Lopez-Zambrano M, Alonso MH, Qu C, McDonnell KJ, Idos GE, Vignali M, Emerson R, Fields P, Guinó E, Santos C, Salazar R, Robins HS, Rennert G, Gruber SB, Moreno V. Lymphocytic infiltration in stage II microsatellite stable colorectal tumors: A retrospective prognosis biomarker analysis. PLoS Med 2020;17:e1003292. [PMID: 32970670 DOI: 10.1371/journal.pmed.1003292] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
205 Liu D. Concomitant dysregulation of the estrogen receptor and BRAF/MEK signaling pathways is common in colorectal cancer and predicts a worse prognosis. Cell Oncol (Dordr) 2019;42:197-209. [PMID: 30645729 DOI: 10.1007/s13402-018-00420-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
206 Vranic S. Microsatellite instability status predicts response to anti-PD-1/PD-L1 therapy regardless the histotype: A comment on recent advances. Bosn J Basic Med Sci 2017;17:274-5. [PMID: 28812534 DOI: 10.17305/bjbms.2017.2366] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
207 Berntsson J, Eberhard J, Nodin B, Leandersson K, Larsson AH, Jirström K. Pre-diagnostic anthropometry, sex, and risk of colorectal cancer according to tumor immune cell composition. Oncoimmunology 2019;8:e1664275. [PMID: 31741761 DOI: 10.1080/2162402X.2019.1664275] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
208 Watari J, Mitani S, Ito C, Tozawa K, Tomita T, Oshima T, Fukui H, Kadowaki S, Natsume S, Senda Y, Tajika M, Hara K, Yatabe Y, Shimizu Y, Muro K, Morimoto T, Hirota S, Das KM, Miwa H. Molecular alterations and PD-L1 expression in non-ampullary duodenal adenocarcinoma: Associations among clinicopathological, immunophenotypic and molecular features. Sci Rep 2019;9:10526. [PMID: 31324814 DOI: 10.1038/s41598-019-46167-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
209 Maby P, Galon J, Latouche JB. Frameshift mutations, neoantigens and tumor-specific CD8(+) T cells in microsatellite unstable colorectal cancers. Oncoimmunology 2016;5:e1115943. [PMID: 27467916 DOI: 10.1080/2162402X.2015.1115943] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
210 Samstein RM, Chan TA. Dissecting microsatellite instability in colorectal cancer: one size does not fit all. Genome Med 2017;9:45. [PMID: 28539127 DOI: 10.1186/s13073-017-0438-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
211 Vainer ED, Kania-Almog J, Zatara G, Levin Y, Vainer GW. Novel Proteome Extraction Method Illustrates a Conserved Immunological Signature of MSI-H Colorectal Tumors. Mol Cell Proteomics 2020;19:1619-31. [PMID: 32641473 DOI: 10.1074/mcp.RA120.002152] [Reference Citation Analysis]
212 Patel SA, Longacre TA, Ladabaum U, Lebensohn A, Lin AY, Haraldsdottir S. Tumor Molecular Testing Guides Anti-PD-1 Therapy and Provides Evidence for Pathogenicity of Mismatch Repair Variants. Oncologist 2018;23:1395-400. [PMID: 30072391 DOI: 10.1634/theoncologist.2018-0108] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
213 Wu MS, Chien CC, Jargalsaikhan G, Ilsan NA, Chen YC. Activation of PERK Contributes to Apoptosis and G2/M Arrest by Microtubule Disruptors in Human Colorectal Carcinoma Cells . Cancers (Basel) 2019;12:E97. [PMID: 31906029 DOI: 10.3390/cancers12010097] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
214 Gatalica Z, Vranic S, Xiu J, Swensen J, Reddy S. High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicine. Fam Cancer. 2016;15:405-412. [PMID: 26875156 DOI: 10.1007/s10689-016-9884-6] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 12.4] [Reference Citation Analysis]
215 Lazarus J, Oneka MD, Barua S, Maj T, Lanfranca MP, Delrosario L, Sun L, Smith JJ, D'Angelica MI, Shia J, Fang JM, Shi J, Di Magliano MP, Zou W, Rao A, Frankel TL. Mathematical Modeling of the Metastatic Colorectal Cancer Microenvironment Defines the Importance of Cytotoxic Lymphocyte Infiltration and Presence of PD-L1 on Antigen Presenting Cells. Ann Surg Oncol 2019;26:2821-30. [PMID: 31250346 DOI: 10.1245/s10434-019-07508-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
216 Guillebon E, Roussille P, Frouin E, Tougeron D. Anti program death-1/anti program death-ligand 1 in digestive cancers. World J Gastrointest Oncol 2015; 7(8): 95-101 [PMID: 26306141 DOI: 10.4251/wjgo.v7.i8.95] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 40] [Article Influence: 5.1] [Reference Citation Analysis]
217 Sobhani I, Rotkopf H, Khazaie K. Bacteria-related changes in host DNA methylation and the risk for CRC. Gut Microbes 2020;12:1800898. [PMID: 32931352 DOI: 10.1080/19490976.2020.1800898] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
218 Boland PM, Yurgelun MB, Boland CR. Recent progress in Lynch syndrome and other familial colorectal cancer syndromes. CA Cancer J Clin. 2018;68:217-231. [PMID: 29485237 DOI: 10.3322/caac.21448] [Cited by in Crossref: 57] [Cited by in F6Publishing: 46] [Article Influence: 14.3] [Reference Citation Analysis]
219 Pramil E, Dillard C, Escargueil AE. Colorectal Cancer and Immunity: From the Wet Lab to Individuals. Cancers (Basel) 2021;13:1713. [PMID: 33916641 DOI: 10.3390/cancers13071713] [Reference Citation Analysis]
220 Li J, Xu J, Yan X, Jin K, Li W, Zhang R. Targeting Interleukin-6 (IL-6) Sensitizes Anti-PD-L1 Treatment in a Colorectal Cancer Preclinical Model. Med Sci Monit. 2018;24:5501-5508. [PMID: 30087314 DOI: 10.12659/msm.907439] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
221 Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer? BMC Med. 2016;14:73. [PMID: 27151159 DOI: 10.1186/s12916-016-0623-5] [Cited by in Crossref: 543] [Cited by in F6Publishing: 484] [Article Influence: 90.5] [Reference Citation Analysis]
222 Corcoran RB. New therapeutic strategies for BRAF mutant colorectal cancers. J Gastrointest Oncol 2015;6:650-9. [PMID: 26697198 DOI: 10.3978/j.issn.2078-6891.2015.076] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
223 Walkowska J, Kallemose T, Jönsson G, Jönsson M, Andersen O, Andersen MH, Svane IM, Langkilde A, Nilbert M, Therkildsen C. Immunoprofiles of colorectal cancer from Lynch syndrome. Oncoimmunology 2019;8:e1515612. [PMID: 30546958 DOI: 10.1080/2162402X.2018.1515612] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
224 D'Alterio C, Nasti G, Polimeno M, Ottaiano A, Conson M, Circelli L, Botti G, Scognamiglio G, Santagata S, De Divitiis C, Nappi A, Napolitano M, Tatangelo F, Pacelli R, Izzo F, Vuttariello E, Botti G, Scala S. CXCR4-CXCL12-CXCR7, TLR2-TLR4, and PD-1/PD-L1 in colorectal cancer liver metastases from neoadjuvant-treated patients. Oncoimmunology. 2016;5:e1254313. [PMID: 28123896 DOI: 10.1080/2162402x.2016.1254313] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
225 Yuan W, Deng D, Li H, Hu X, Shang X, Hou X, Jiang H, He H. IFNγ/PD-L1 Signaling Improves the Responsiveness of Anti-PD-1 Therapy in Colorectal Cancer: An in vitro Study. Onco Targets Ther 2021;14:3051-62. [PMID: 33994797 DOI: 10.2147/OTT.S294136] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
226 Wang J, Liu J, Tian F, Zhan Y, Kong D. Cyclin-dependent kinase 9 expression and its association with CD8+ T cell infiltration in microsatellite-stable colorectal cancer. Oncol Lett 2019;18:6046-56. [PMID: 31788079 DOI: 10.3892/ol.2019.10970] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
227 Cho J, Lee J, Bang H, Kim ST, Park SH, An JY, Choi MG, Lee JH, Sohn TS, Bae JM. Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability. Oncotarget. 2017;8:13320-13328. [PMID: 28076847 DOI: 10.18632/oncotarget.14519] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 8.2] [Reference Citation Analysis]
228 Graham DM, Coyle VM, Kennedy RD, Wilson RH. Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer. Curr Colorectal Cancer Rep 2016;12:141-50. [PMID: 27340376 DOI: 10.1007/s11888-016-0312-y] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
229 Cohen R, Colle R, Pudlarz T, Heran M, Duval A, Svrcek M, André T. Immune Checkpoint Inhibition in Metastatic Colorectal Cancer Harboring Microsatellite Instability or Mismatch Repair Deficiency. Cancers (Basel) 2021;13:1149. [PMID: 33800202 DOI: 10.3390/cancers13051149] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
230 Lee JM, Botesteanu DA, Tomita Y, Yuno A, Lee MJ, Kohn EC, Annunziata CM, Matulonis U, MacDonald LA, Nair JR, Macneill KM, Trepel JB. Patients with BRCA mutated ovarian cancer may have fewer circulating MDSC and more peripheral CD8+ T cells compared with women with BRCA wild-type disease during the early disease course. Oncol Lett 2019;18:3914-24. [PMID: 31516602 DOI: 10.3892/ol.2019.10731] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
231 Christofi T, Baritaki S, Falzone L, Libra M, Zaravinos A. Current Perspectives in Cancer Immunotherapy. Cancers (Basel) 2019;11:E1472. [PMID: 31575023 DOI: 10.3390/cancers11101472] [Cited by in Crossref: 64] [Cited by in F6Publishing: 52] [Article Influence: 21.3] [Reference Citation Analysis]
232 Sudoyo AW, Kurniawan AN, Kusumo GD, Putra TP, Rexana FA, Yunus M, Budiyati AD, Kurniawan D, Utama A, Utomo AR. Increased CD8 Tumor Infiltrating Lymphocytes in Colorectal Cancer Microenvironment Supports an Adaptive Immune Resistance Mechanism of PD-L1 Expression. Asian Pac J Cancer Prev 2019;20:3421-7. [PMID: 31759368 DOI: 10.31557/APJCP.2019.20.11.3421] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
233 Inamura K. Colorectal Cancers: An Update on Their Molecular Pathology. Cancers (Basel). 2018;10. [PMID: 29361689 DOI: 10.3390/cancers10010026] [Cited by in Crossref: 62] [Cited by in F6Publishing: 58] [Article Influence: 15.5] [Reference Citation Analysis]
234 Millard T, Kunk PR, Ramsdale E, Rahma OE. Current debate in the oncologic management of rectal cancer. World J Gastrointest Oncol 2016; 8(10): 715-724 [PMID: 27795811 DOI: 10.4251/wjgo.v8.i10.715] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
235 Scarpa M, Ruffolo C, Kotsafti A, Canal F, Erroi F, Basato S, DallAgnese L, Fiorot A, Pozza A, Brun P, Bassi N, Dei Tos A, Castoro C, Castagliuolo I, Scarpa M. MLH1 Deficiency Down-Regulates TLR4 Expression in Sporadic Colorectal Cancer. Front Mol Biosci 2021;8:624873. [PMID: 34026821 DOI: 10.3389/fmolb.2021.624873] [Reference Citation Analysis]
236 Schirripa M, Cohen SA, Battaglin F, Lenz HJ. Biomarker-driven and molecular targeted therapies for colorectal cancers. Semin Oncol 2018;45:124-32. [PMID: 30262397 DOI: 10.1053/j.seminoncol.2017.06.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
237 Wang H, Wang X, Xu L, Zhang J, Cao H. Analysis of the transcriptomic features of microsatellite instability subtype colon cancer. BMC Cancer 2019;19:605. [PMID: 31221124 DOI: 10.1186/s12885-019-5802-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
238 Deshpande M, Romanski PA, Rosenwaks Z, Gerhardt J. Gynecological Cancers Caused by Deficient Mismatch Repair and Microsatellite Instability. Cancers (Basel) 2020;12:E3319. [PMID: 33182707 DOI: 10.3390/cancers12113319] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
239 Taube JM, Young GD, McMiller TL, Chen S, Salas JT, Pritchard TS, Xu H, Meeker AK, Fan J, Cheadle C, Berger AE, Pardoll DM, Topalian SL. Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade. Clin Cancer Res. 2015;21:3969-3976. [PMID: 25944800 DOI: 10.1158/1078-0432.ccr-15-0244] [Cited by in Crossref: 154] [Cited by in F6Publishing: 105] [Article Influence: 22.0] [Reference Citation Analysis]
240 Ouyang R, Li Z, Peng P, Zhang J, Liu J, Qin M, Huang J. Exploration of the relationship between tumor mutation burden and immune infiltrates in colon adenocarcinoma. Int J Med Sci 2021;18:685-94. [PMID: 33437203 DOI: 10.7150/ijms.51918] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
241 Park JH, Powell AG, Roxburgh CS, Horgan PG, McMillan DC, Edwards J. Mismatch repair status in patients with primary operable colorectal cancer: associations with the local and systemic tumour environment. Br J Cancer 2016;114:562-70. [PMID: 26859693 DOI: 10.1038/bjc.2016.17] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 7.7] [Reference Citation Analysis]
242 Winer A, Ghatalia P, Bubes N, Anari F, Varshavsky A, Kasireddy V, Liu Y, El-Deiry WS. Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD-1/PDL-1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer. Oncologist 2019;24:1416-9. [PMID: 31444293 DOI: 10.1634/theoncologist.2018-0686] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
243 Francescangeli F, De Angelis ML, Zeuner A. Dietary Factors in the Control of Gut Homeostasis, Intestinal Stem Cells, and Colorectal Cancer. Nutrients 2019;11:E2936. [PMID: 31816977 DOI: 10.3390/nu11122936] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
244 Pedrosa L, Esposito F, Thomson TM, Maurel J. The Tumor Microenvironment in Colorectal Cancer Therapy. Cancers (Basel) 2019;11:E1172. [PMID: 31416205 DOI: 10.3390/cancers11081172] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 8.7] [Reference Citation Analysis]
245 Hamada T, Cao Y, Qian ZR, Masugi Y, Nowak JA, Yang J, Song M, Mima K, Kosumi K, Liu L, Shi Y, da Silva A, Gu M, Li W, Keum N, Zhang X, Wu K, Meyerhardt JA, Giovannucci EL, Giannakis M, Rodig SJ, Freeman GJ, Nevo D, Wang M, Chan AT, Fuchs CS, Nishihara R, Ogino S. Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1 Ligand 1) Expression Status. J Clin Oncol. 2017;35:1836-1844. [PMID: 28406723 DOI: 10.1200/jco.2016.70.7547] [Cited by in Crossref: 74] [Cited by in F6Publishing: 55] [Article Influence: 14.8] [Reference Citation Analysis]
246 Xiang R, Rong Y, Ge Y, Song W, Ren J, Fu T. Cell differentiation trajectory predicts patient potential immunotherapy response and prognosis in gastric cancer. Aging (Albany NY) 2021;13:5928-45. [PMID: 33612483 DOI: 10.18632/aging.202515] [Reference Citation Analysis]
247 Medler TR, Blair TC, Crittenden MR, Gough MJ. Defining Immunogenic and Radioimmunogenic Tumors. Front Oncol 2021;11:667075. [PMID: 33816320 DOI: 10.3389/fonc.2021.667075] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
248 Bever KM, Le DT. DNA repair defects and implications for immunotherapy. J Clin Invest 2018;128:4236-42. [PMID: 30272580 DOI: 10.1172/JCI122010] [Cited by in Crossref: 32] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
249 Li Y, Liang L, Dai W, Cai G, Xu Y, Li X, Li Q, Cai S. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer. Mol Cancer 2016;15:55. [PMID: 27552968 DOI: 10.1186/s12943-016-0539-x] [Cited by in Crossref: 113] [Cited by in F6Publishing: 129] [Article Influence: 18.8] [Reference Citation Analysis]
250 Giraldo NA, Sanchez-Salas R, Peske JD, Vano Y, Becht E, Petitprez F, Validire P, Ingels A, Cathelineau X, Fridman WH, Sautès-Fridman C. The clinical role of the TME in solid cancer. Br J Cancer 2019;120:45-53. [PMID: 30413828 DOI: 10.1038/s41416-018-0327-z] [Cited by in Crossref: 85] [Cited by in F6Publishing: 93] [Article Influence: 21.3] [Reference Citation Analysis]
251 Puccini A, Berger MD, Zhang W, Lenz HJ. What We Know About Stage II and III Colon Cancer: It's Still Not Enough. Target Oncol 2017;12:265-75. [PMID: 28504299 DOI: 10.1007/s11523-017-0494-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
252 Seliger B. The Role of the Lymphocyte Functional Crosstalk and Regulation in the Context of Checkpoint Inhibitor Treatment-Review. Front Immunol 2019;10:2043. [PMID: 31555274 DOI: 10.3389/fimmu.2019.02043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
253 Shukla SA, Howitt BE, Wu CJ, Konstantinopoulos PA. Predicted neoantigen load in non-hypermutated endometrial cancers: Correlation with outcome and tumor-specific genomic alterations. Gynecol Oncol Rep 2017;19:42-5. [PMID: 28070553 DOI: 10.1016/j.gore.2016.12.009] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
254 Dou R, Nishihara R, Cao Y, Hamada T, Mima K, Masuda A, Masugi Y, Shi Y, Gu M, Li W, da Silva A, Nosho K, Zhang X, Meyerhardt JA, Giovannucci EL, Chan AT, Fuchs CS, Qian ZR, Ogino S. MicroRNA let-7, T Cells, and Patient Survival in Colorectal Cancer. Cancer Immunol Res. 2016;4:927-935. [PMID: 27737877 DOI: 10.1158/2326-6066.cir-16-0112] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 4.7] [Reference Citation Analysis]
255 Norton SE, Ward-Hartstonge KA, Taylor ES, Kemp RA. Immune cell interplay in colorectal cancer prognosis. World J Gastrointest Oncol 2015; 7(10): 221-232 [PMID: 26483876 DOI: 10.4251/wjgo.v7.i10.221] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
256 Cho J, Chang YH, Heo YJ, Kim S, Kim NK, Park JO, Kang WK, Lee J, Kim KM. Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instability. ESMO Open. 2018;3:e000326. [PMID: 29636988 DOI: 10.1136/esmoopen-2018-000326] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 7.5] [Reference Citation Analysis]
257 Alburquerque-González B, López-Calderón FF, López-Abellán MD, Esteban-Gil Á, García-Solano J, Conesa-Zamora P. Biology and Therapeutic Targets of Colorectal Serrated Adenocarcinoma; Clues for a Histologically Based Treatment against an Aggressive Tumor. Int J Mol Sci 2020;21:E1991. [PMID: 32183342 DOI: 10.3390/ijms21061991] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
258 Mouw KW, D'Andrea AD, Konstantinopoulos PA. Nucleotide excision repair (NER) alterations as evolving biomarkers and therapeutic targets in epithelial cancers. Oncoscience 2015;2:942-3. [PMID: 26909362 DOI: 10.18632/oncoscience.283] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
259 Xiao Y, Freeman GJ. The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy. Cancer Discov. 2015;5:16-18. [PMID: 25583798 DOI: 10.1158/2159-8290.cd-14-1397] [Cited by in Crossref: 199] [Cited by in F6Publishing: 131] [Article Influence: 28.4] [Reference Citation Analysis]
260 Howitt BE, Strickland KC, Sholl LM, Rodig S, Ritterhouse LL, Chowdhury D, D'Andrea AD, Matulonis UA, Konstantinopoulos PA. Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression. Oncoimmunology 2017;6:e1277308. [PMID: 28344892 DOI: 10.1080/2162402X.2016.1277308] [Cited by in Crossref: 54] [Cited by in F6Publishing: 24] [Article Influence: 10.8] [Reference Citation Analysis]
261 Bae JM, Yoo SY, Kim JH, Kang GH. Immune landscape and biomarkers for immuno-oncology in colorectal cancers. J Pathol Transl Med 2020;54:351-60. [PMID: 32580539 DOI: 10.4132/jptm.2020.05.15] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
262 Palmerini E, Agostinelli C, Picci P, Pileri S, Marafioti T, Lollini PL, Scotlandi K, Longhi A, Benassi MS, Ferrari S. Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1. Oncotarget 2017;8:111836-46. [PMID: 29340095 DOI: 10.18632/oncotarget.22912] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 6.2] [Reference Citation Analysis]
263 Echterdiek F, Janikovits J, Staffa L, Müller M, Lahrmann B, Frühschütz M, Hartog B, Nelius N, Benner A, Tariverdian M, von Knebel Doeberitz M, Grabe N, Kloor M. Low density of FOXP3-positive T cells in normal colonic mucosa is related to the presence of beta2-microglobulin mutations in Lynch syndrome-associated colorectal cancer. Oncoimmunology 2016;5:e1075692. [PMID: 27057447 DOI: 10.1080/2162402X.2015.1075692] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 3.1] [Reference Citation Analysis]
264 Ott E, Bilonda L, Dansette D, Deleine C, Duchalais E, Podevin J, Volteau C, Bennouna J, Touchefeu Y, Fourquier P, El Alami Thomas W, Chetritt J, Bezieau S, Denis M, Toquet C, Mosnier JF, Jarry A, Bossard C. The density of Tbet+ tumor-infiltrating T lymphocytes reflects an effective and druggable preexisting adaptive antitumor immune response in colorectal cancer, irrespective of the microsatellite status. Oncoimmunology 2019;8:e1562834. [PMID: 30906656 DOI: 10.1080/2162402X.2018.1562834] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
265 Westdorp H, Fennemann FL, Weren RD, Bisseling TM, Ligtenberg MJ, Figdor CG, Schreibelt G, Hoogerbrugge N, Wimmers F, de Vries IJ. Opportunities for immunotherapy in microsatellite instable colorectal cancer. Cancer Immunol Immunother 2016;65:1249-59. [PMID: 27060000 DOI: 10.1007/s00262-016-1832-7] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 7.8] [Reference Citation Analysis]
266 Puzzoni M, Silvestris N, Leone F, Giampieri R, Faloppi L, Demurtas L, Dell'Aquila E, Marino D, Brunetti O, Garattini SK, Ongaro E, Astara G, Orgiano L, Aprile G, Santini D, Scartozzi M. The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following? Target Oncol 2016;11:593-603. [PMID: 27184491 DOI: 10.1007/s11523-016-0437-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
267 Strasser K, Birnleitner H, Beer A, Pils D, Gerner MC, Schmetterer KG, Bachleitner-Hofmann T, Stift A, Bergmann M, Oehler R. Immunological differences between colorectal cancer and normal mucosa uncover a prognostically relevant immune cell profile. Oncoimmunology 2019;8:e1537693. [PMID: 30713795 DOI: 10.1080/2162402X.2018.1537693] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
268 Sinnadurai M, McDonald KL. Immune checkpoint inhibition and its relationship with hypermutation phenoytype as a potential treatment for Glioblastoma. J Neurooncol 2017;132:359-72. [PMID: 28293764 DOI: 10.1007/s11060-017-2390-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
269 Zhao Y, Zhang W, Huo M, Wang P, Liu X, Wang Y, Li Y, Zhou Z, Xu N, Zhu H. XBP1 regulates the protumoral function of tumor-associated macrophages in human colorectal cancer. Signal Transduct Target Ther 2021;6:357. [PMID: 34667145 DOI: 10.1038/s41392-021-00761-7] [Reference Citation Analysis]
270 Melero I, Berman DM, Aznar MA, Korman AJ, Pérez Gracia JL, Haanen J. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer 2015;15:457-72. [PMID: 26205340 DOI: 10.1038/nrc3973] [Cited by in Crossref: 418] [Cited by in F6Publishing: 387] [Article Influence: 59.7] [Reference Citation Analysis]
271 Yu Y, Zhang J, Ni L, Zhu Y, Yu H, Teng Y, Lin L, Xue Z, Xue X, Shen X, Song H, Su X, Sun W, Cai Z. Neoantigen-reactive T cells exhibit effective anti-tumor activity against colorectal cancer. Hum Vaccin Immunother 2021;:1-11. [PMID: 33689574 DOI: 10.1080/21645515.2021.1891814] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
272 Xie H, Wang W, Qi W, Jin W, Xia B. Targeting DNA Repair Response Promotes Immunotherapy in Ovarian Cancer: Rationale and Clinical Application. Front Immunol 2021;12:661115. [PMID: 34712221 DOI: 10.3389/fimmu.2021.661115] [Reference Citation Analysis]
273 Surana R, Pant S. Immunotherapy in Gastrointestinal Malignancies. Adv Exp Med Biol 2021;1342:259-72. [PMID: 34972968 DOI: 10.1007/978-3-030-79308-1_8] [Reference Citation Analysis]
274 Ito F, Ku AW, Bucsek MJ, Muhitch JB, Vardam-Kaur T, Kim M, Fisher DT, Camoriano M, Khoury T, Skitzki JJ, Gollnick SO, Evans SS. Immune Adjuvant Activity of Pre-Resectional Radiofrequency Ablation Protects against Local and Systemic Recurrence in Aggressive Murine Colorectal Cancer. PLoS One. 2015;10:e0143370. [PMID: 26599402 DOI: 10.1371/journal.pone.0143370] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
275 Ogino S, Nowak JA, Hamada T, Phipps AI, Peters U, Milner DA, Giovannucci EL, Nishihara R, Giannakis M, Garrett WS, Song M. Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine. Gut. 2018;67:1168-1180. [PMID: 29437869 DOI: 10.1136/gutjnl-2017-315537] [Cited by in Crossref: 93] [Cited by in F6Publishing: 91] [Article Influence: 23.3] [Reference Citation Analysis]
276 Lynch HT, Lanspa S, Shaw T, Casey MJ, Rendell M, Stacey M, Townley T, Snyder C, Hitchins M, Bailey-Wilson J. Phenotypic and genotypic heterogeneity of Lynch syndrome: a complex diagnostic challenge. Fam Cancer 2018;17:403-14. [PMID: 29071502 DOI: 10.1007/s10689-017-0053-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
277 Cao W, Ma X, Fischer JV, Sun C, Kong B, Zhang Q. Immunotherapy in endometrial cancer: rationale, practice and perspectives. Biomark Res 2021;9:49. [PMID: 34134781 DOI: 10.1186/s40364-021-00301-z] [Reference Citation Analysis]
278 Valle L, Vilar E, Tavtigian SV, Stoffel EM. Genetic predisposition to colorectal cancer: syndromes, genes, classification of genetic variants and implications for precision medicine. J Pathol 2019;247:574-88. [PMID: 30584801 DOI: 10.1002/path.5229] [Cited by in Crossref: 49] [Cited by in F6Publishing: 39] [Article Influence: 16.3] [Reference Citation Analysis]
279 Jung K, Heishi T, Incio J, Huang Y, Beech EY, Pinter M, Ho WW, Kawaguchi K, Rahbari NN, Chung E, Kim JK, Clark JW, Willett CG, Yun SH, Luster AD, Padera TP, Jain RK, Fukumura D. Targeting CXCR4-dependent immunosuppressive Ly6Clow monocytes improves antiangiogenic therapy in colorectal cancer. Proc Natl Acad Sci USA. 2017;114:10455-10460. [PMID: 28900008 DOI: 10.1073/pnas.1710754114] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 10.2] [Reference Citation Analysis]
280 Cui G. The Mechanisms Leading to Distinct Responses to PD-1/PD-L1 Blockades in Colorectal Cancers With Different MSI Statuses. Front Oncol 2021;11:573547. [PMID: 33763344 DOI: 10.3389/fonc.2021.573547] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
281 Kim JH, Park HE, Cho NY, Lee HS, Kang GH. Characterisation of PD-L1-positive subsets of microsatellite-unstable colorectal cancers. Br J Cancer 2016;115:490-6. [PMID: 27404452 DOI: 10.1038/bjc.2016.211] [Cited by in Crossref: 59] [Cited by in F6Publishing: 59] [Article Influence: 9.8] [Reference Citation Analysis]
282 Kim JH, Kim BJ, Kim HS, Kim JH. Current Status and Perspective of Immunotherapy in Gastrointestinal Cancers. J Cancer 2016;7:1599-604. [PMID: 27698896 DOI: 10.7150/jca.16208] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
283 Fan A, Wang B, Wang X, Nie Y, Fan D, Zhao X, Lu Y. Immunotherapy in colorectal cancer: current achievements and future perspective. Int J Biol Sci 2021;17:3837-49. [PMID: 34671202 DOI: 10.7150/ijbs.64077] [Reference Citation Analysis]
284 Lin A, Zhang J, Luo P. Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer. Front Immunol 2020;11:2039. [PMID: 32903444 DOI: 10.3389/fimmu.2020.02039] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 8.5] [Reference Citation Analysis]
285 Chang K, Taggart MW, Reyes-Uribe L, Borras E, Riquelme E, Barnett RM, Leoni G, San Lucas FA, Catanese MT, Mori F, Diodoro MG, You YN, Hawk ET, Roszik J, Scheet P, Kopetz S, Nicosia A, Scarselli E, Lynch PM, McAllister F, Vilar E. Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome. JAMA Oncol 2018;4:1085-92. [PMID: 29710228 DOI: 10.1001/jamaoncol.2018.1482] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 11.7] [Reference Citation Analysis]
286 Xu X, Ma J, Yu G, Qiu Q, Zhang W, Cao F. Effective Predictor of Colorectal Cancer Survival Based on Exclusive Expression Pattern Among Different Immune Cell Infiltration. J Histochem Cytochem 2021;69:271-86. [PMID: 33550891 DOI: 10.1369/0022155421991938] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
287 Zhang Y, Li J, Wang B, Chen T, Chen Y, Ma W. LDH-A negatively regulates dMMR in colorectal cancer. Cancer Sci 2021;112:3050-63. [PMID: 34110068 DOI: 10.1111/cas.15020] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
288 Bai J, Chen H, Bai X. Relationship between microsatellite status and immune microenvironment of colorectal cancer and its application to diagnosis and treatment. J Clin Lab Anal 2021;35:e23810. [PMID: 33938589 DOI: 10.1002/jcla.23810] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
289 Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016;8:328rv4. [PMID: 26936508 DOI: 10.1126/scitranslmed.aad7118] [Cited by in Crossref: 1022] [Cited by in F6Publishing: 1034] [Article Influence: 170.3] [Reference Citation Analysis]
290 Grizzi F, Basso G, Borroni EM, Cavalleri T, Bianchi P, Stifter S, Chiriva-Internati M, Malesci A, Laghi L. Evolving notions on immune response in colorectal cancer and their implications for biomarker development. Inflamm Res. 2018;67:375-389. [PMID: 29322204 DOI: 10.1007/s00011-017-1128-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
291 Hinchcliff E, Hong D, Le H, Chisholm G, Iyer R, Naing A, Hwu P, Jazaeri A. Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials. Gynecol Oncol 2018;151:407-13. [PMID: 30366646 DOI: 10.1016/j.ygyno.2018.10.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
292 Dal Buono A, Gaiani F, Poliani L, Correale C, Laghi L. Defects in MMR Genes as a Seminal Example of Personalized Medicine: From Diagnosis to Therapy. J Pers Med 2021;11:1333. [PMID: 34945805 DOI: 10.3390/jpm11121333] [Reference Citation Analysis]
293 Miyamoto Y, Zhang W, Lenz HJ. Molecular Landscape and Treatment Options for Patients with Metastatic Colorectal Cancer. Indian J Surg Oncol 2017;8:580-90. [PMID: 29203992 DOI: 10.1007/s13193-016-0543-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
294 Khoury JD, Wang WL, Prieto VG, Medeiros LJ, Kalhor N, Hameed M, Broaddus R, Hamilton SR. Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial. Clin Cancer Res 2018;24:521-31. [PMID: 28839110 DOI: 10.1158/1078-0432.CCR-17-1597] [Cited by in Crossref: 37] [Cited by in F6Publishing: 18] [Article Influence: 7.4] [Reference Citation Analysis]
295 Kuang C, Park Y, Augustin RC, Lin Y, Hartman DJ, Seigh L, Pai RK, Sun W, Bahary N, Ohr J, Rhee JC, Marks SM, Beasley HS, Shuai Y, Herman JG, Zarour HM, Chu E, Lee JJ, Krishnamurthy A. Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis. Clin Epigenetics 2022;14:3. [PMID: 34991708 DOI: 10.1186/s13148-021-01226-y] [Reference Citation Analysis]
296 Lai E, Liscia N, Donisi C, Mariani S, Tolu S, Pretta A, Persano M, Pinna G, Balconi F, Pireddu A, Impera V, Dubois M, Migliari M, Spanu D, Saba G, Camera S, Musio F, Ziranu P, Puzzoni M, Demurtas L, Pusceddu V, Dettori M, Massa E, Atzori F, Dessì M, Astara G, Madeddu C, Scartozzi M. Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer. Cancers (Basel) 2020;12:E1214. [PMID: 32413973 DOI: 10.3390/cancers12051214] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
297 Schaue D, Mcbride WH. Opportunities and challenges of radiotherapy for treating cancer. Nat Rev Clin Oncol 2015;12:527-40. [DOI: 10.1038/nrclinonc.2015.120] [Cited by in Crossref: 174] [Cited by in F6Publishing: 174] [Article Influence: 24.9] [Reference Citation Analysis]
298 Mangaonkar A, Mondal AK, Fulzule S, Pundkar C, Park EJ, Jillella A, Kota V, Xu H, Savage NM, Shi H, Munn D, Kolhe R. A novel immunohistochemical score to predict early mortality in acute myeloid leukemia patients based on indoleamine 2,3 dioxygenase expression. Sci Rep 2017;7:12892. [PMID: 29038460 DOI: 10.1038/s41598-017-12940-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
299 Han XJ, Alu A, Xiao YN, Wei YQ, Wei XW. Hyperprogression: A novel response pattern under immunotherapy. Clin Transl Med 2020;10:e167. [PMID: 32997401 DOI: 10.1002/ctm2.167] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
300 Schirripa M, Zhang W, Yang D, Cao S, Okazaki S, Loupakis F, Berger MD, Ning Y, Miyamoto Y, Suenaga M, Alberti G, West JD, Lonardi S, Khoukaz T, Bergamo F, Battaglin F, Antoniotti C, Falcone A, Stintzing S, Heinemann V, Lenz HJ. NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients. PLoS One 2018;13:e0193640. [PMID: 29522543 DOI: 10.1371/journal.pone.0193640] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
301 Pang SW, Awi NJ, Armon S, Lim WW, Low JS, Peh KB, Peh SC, Teow SY. Current Update of Laboratory Molecular Diagnostics Advancement in Management of Colorectal Cancer (CRC). Diagnostics (Basel) 2019;10:E9. [PMID: 31877940 DOI: 10.3390/diagnostics10010009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
302 Rieth J, Subramanian S. Mechanisms of Intrinsic Tumor Resistance to Immunotherapy. Int J Mol Sci 2018;19:E1340. [PMID: 29724044 DOI: 10.3390/ijms19051340] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 8.8] [Reference Citation Analysis]
303 Zhang CM, Lv JF, Gong L, Yu LY, Chen XP, Zhou HH, Fan L. Role of Deficient Mismatch Repair in the Personalized Management of Colorectal Cancer. Int J Environ Res Public Health 2016;13:E892. [PMID: 27618077 DOI: 10.3390/ijerph13090892] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
304 Deng X, Pan Y, Yang M, Liu Y, Li J. PLOD3 Is Associated with Immune Cell Infiltration and Genomic Instability in Colon Adenocarcinoma. Biomed Res Int 2021;2021:4714526. [PMID: 34239923 DOI: 10.1155/2021/4714526] [Reference Citation Analysis]
305 Bellone S, Roque DM, Siegel ER, Buza N, Hui P, Bonazzoli E, Guglielmi A, Zammataro L, Nagarkatti N, Zaidi S, Lee J, Silasi DA, Huang GS, Andikyan V, Damast S, Clark M, Azodi M, Schwartz PE, Tymon-Rosario JR, Harold JA, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Alexandrov LB, Iwasaki A, Kong Y, Song E, Dong W, Elvin JA, Choi J, Santin AD. A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability. Cancer 2021. [PMID: 34875107 DOI: 10.1002/cncr.34025] [Reference Citation Analysis]
306 Zhu L, Xu Z, Wu Y, Liu P, Qian J, Yu S, Xia B, Lai J, Ma S, Wu Z. Prophylactic chemotherapeutic hyperthermic intraperitoneal perfusion reduces peritoneal metastasis in gastric cancer: a retrospective clinical study. BMC Cancer 2020;20:827. [PMID: 32867714 DOI: 10.1186/s12885-020-07339-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
307 Minchom A, Aversa C, Lopez J. Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies. Ther Adv Med Oncol 2018;10:1758835918786658. [PMID: 30023007 DOI: 10.1177/1758835918786658] [Cited by in Crossref: 65] [Cited by in F6Publishing: 59] [Article Influence: 16.3] [Reference Citation Analysis]
308 Boussios S, Ozturk MA, Moschetta M, Karathanasi A, Zakynthinakis-Kyriakou N, Katsanos KH, Christodoulou DK, Pavlidis N. The Developing Story of Predictive Biomarkers in Colorectal Cancer. J Pers Med 2019;9:E12. [PMID: 30736475 DOI: 10.3390/jpm9010012] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 15.3] [Reference Citation Analysis]
309 Pilger D, Seymour LW, Jackson SP. Interfaces between cellular responses to DNA damage and cancer immunotherapy. Genes Dev 2021;35:602-18. [PMID: 33888558 DOI: 10.1101/gad.348314.121] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
310 Zhao L, Yu H, Yi S, Peng X, Su P, Xiao Z, Liu R, Tang A, Li X, Liu F, Shen S. The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer. Oncotarget. 2016;7:45370-45384. [PMID: 27248318 DOI: 10.18632/oncotarget.9659] [Cited by in Crossref: 107] [Cited by in F6Publishing: 118] [Article Influence: 26.8] [Reference Citation Analysis]
311 Procaccio L, Schirripa M, Fassan M, Vecchione L, Bergamo F, Prete AA, Intini R, Manai C, Dadduzio V, Boscolo A. Immunotherapy in Gastrointestinal Cancers. Biomed Res Int. 2017;2017:4346576. [PMID: 28758114 DOI: 10.1155/2017/4346576] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
312 Chang L, Chang M, Chang HM, Chang F. Expending Role of Microsatellite Instability in Diagnosis and Treatment of Colorectal Cancers. J Gastrointest Cancer 2017;48:305-13. [PMID: 28699072 DOI: 10.1007/s12029-017-9991-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
313 Angriman I, Furian L, Scarpa M, Fassan M, Morgan S, Porzionato A, Kotsafti A, Saadeh L, Silvestre C, De Caro R, Carraro A, Tedeschi U, Bardini R, Rigotti P, Rugge M, Castoro C, Castagliuolo I, Scarpa M. Effects of immune suppression for transplantation on inflammatory colorectal cancer progression. Oncogenesis 2018;7:46. [PMID: 29915171 DOI: 10.1038/s41389-018-0055-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
314 O'Neil BH, Wallmark JM, Lorente D, Elez E, Raimbourg J, Gomez-Roca C, Ejadi S, Piha-Paul SA, Stein MN, Abdul Razak AR, Dotti K, Santoro A, Cohen RB, Gould M, Saraf S, Stein K, Han SW. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma. PLoS One. 2017;12:e0189848. [PMID: 29284010 DOI: 10.1371/journal.pone.0189848] [Cited by in Crossref: 91] [Cited by in F6Publishing: 92] [Article Influence: 18.2] [Reference Citation Analysis]
315 Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer. 2017;17:79-92. [PMID: 28050011 DOI: 10.1038/nrc.2016.126] [Cited by in Crossref: 338] [Cited by in F6Publishing: 307] [Article Influence: 67.6] [Reference Citation Analysis]
316 Kawazoe A, Shitara K. Next-generation sequencing and biomarkers for gastric cancer: what is the future? Ther Adv Med Oncol 2019;11:1758835919848189. [PMID: 31258627 DOI: 10.1177/1758835919848189] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
317 Chae YK, Anker JF, Bais P, Namburi S, Giles FJ, Chuang JH. Mutations in DNA repair genes are associated with increased neo-antigen load and activated T cell infiltration in lung adenocarcinoma. Oncotarget 2018;9:7949-60. [PMID: 29487705 DOI: 10.18632/oncotarget.23742] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 7.2] [Reference Citation Analysis]
318 Wang L, Ren F, Wang Q, Baldridge LA, Monn MF, Fisher KW, Sheng W, Zhou X, Du X, Cheng L. Significance of Programmed Death Ligand 1 (PD-L1) Immunohistochemical Expression in Colorectal Cancer. Mol Diagn Ther 2016;20:175-81. [PMID: 26891728 DOI: 10.1007/s40291-016-0188-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
319 Iyevleva AG, Imyanitov EN. Cytotoxic and targeted therapy for hereditary cancers. Hered Cancer Clin Pract. 2016;14:17. [PMID: 27555886 DOI: 10.1186/s13053-016-0057-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 4.3] [Reference Citation Analysis]
320 Alves Martins BA, de Bulhões GF, Cavalcanti IN, Martins MM, de Oliveira PG, Martins AMA. Biomarkers in Colorectal Cancer: The Role of Translational Proteomics Research. Front Oncol 2019;9:1284. [PMID: 31828035 DOI: 10.3389/fonc.2019.01284] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 10.7] [Reference Citation Analysis]
321 Lopez-Beltran A, Henriques V, Cimadamore A, Santoni M, Cheng L, Gevaert T, Blanca A, Massari F, Scarpelli M, Montironi R. The Identification of Immunological Biomarkers in Kidney Cancers. Front Oncol 2018;8:456. [PMID: 30450335 DOI: 10.3389/fonc.2018.00456] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
322 Shien K, Papadimitrakopoulou VA, Wistuba II. Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer. Lung Cancer 2016;99:79-87. [PMID: 27565919 DOI: 10.1016/j.lungcan.2016.06.016] [Cited by in Crossref: 69] [Cited by in F6Publishing: 75] [Article Influence: 11.5] [Reference Citation Analysis]
323 Zheng K, Wan H, Zhang J, Shan G, Chai N, Li D, Fang N, Liu L, Zhang J, Du R, Wu Q, Li X, Zhang C. A novel NGS-based microsatellite instability (MSI) status classifier with 9 loci for colorectal cancer patients. J Transl Med 2020;18:215. [PMID: 32466784 DOI: 10.1186/s12967-020-02373-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
324 Permata TBM, Hagiwara Y, Sato H, Yasuhara T, Oike T, Gondhowiardjo S, Held KD, Nakano T, Shibata A. Base excision repair regulates PD-L1 expression in cancer cells. Oncogene 2019;38:4452-66. [PMID: 30755733 DOI: 10.1038/s41388-019-0733-6] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 12.3] [Reference Citation Analysis]
325 Essakly A, Loeser H, Kraemer M, Alakus H, Chon SH, Zander T, Buettner R, Hillmer AM, Bruns CJ, Schroeder W, Gebauer F, Quaas A. PIK3CA and KRAS Amplification in Esophageal Adenocarcinoma and their Impact on the Inflammatory Tumor Microenvironment and Prognosis. Transl Oncol 2020;13:157-64. [PMID: 31865178 DOI: 10.1016/j.tranon.2019.10.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
326 Munhoz RR, Postow MA. Recent advances in understanding antitumor immunity. F1000Res 2016;5:2545. [PMID: 27803807 DOI: 10.12688/f1000research.9356.1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
327 Lin EM, Gong J, Klempner SJ, Chao J. Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond. World J Gastroenterol 2018; 24(25): 2686-2697 [PMID: 29991874 DOI: 10.3748/wjg.v24.i25.2686] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
328 Ghatalia P, Nagarathinam R, Cooper H, Geynisman DM, El-Deiry WS. Mismatch repair deficient metastatic colon cancer and urothelial cancer: A case report of sequential immune checkpoint therapy. Cancer Biol Ther 2017;18:651-4. [PMID: 28726535 DOI: 10.1080/15384047.2017.1356506] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
329 Szeponik L, Ahlmanner F, Sundström P, Rodin W, Gustavsson B, Bexe Lindskog E, Wettergren Y, Quiding-Järbrink M. Intratumoral regulatory T cells from colon cancer patients comprise several activated effector populations. BMC Immunol 2021;22:58. [PMID: 34407765 DOI: 10.1186/s12865-021-00449-1] [Reference Citation Analysis]
330 Pawłowska A, Suszczyk D, Okła K, Barczyński B, Kotarski J, Wertel I. Immunotherapies based on PD-1/PD-L1 pathway inhibitors in ovarian cancer treatment. Clin Exp Immunol 2019;195:334-44. [PMID: 30582756 DOI: 10.1111/cei.13255] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
331 Gopalakrishnan D, Koshkin VS, Ornstein MC, Papatsoris A, Grivas P. Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook. Ther Clin Risk Manag 2018;14:1019-40. [PMID: 29892196 DOI: 10.2147/TCRM.S158753] [Cited by in Crossref: 46] [Cited by in F6Publishing: 22] [Article Influence: 11.5] [Reference Citation Analysis]
332 Rieke DT, Ochsenreither S, Klinghammer K, Seiwert TY, Klauschen F, Tinhofer I, Keilholz U. Methylation of RAD51B, XRCC3 and other homologous recombination genes is associated with expression of immune checkpoints and an inflammatory signature in squamous cell carcinoma of the head and neck, lung and cervix. Oncotarget 2016;7:75379-93. [PMID: 27683114 DOI: 10.18632/oncotarget.12211] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
333 Gu T, De Jesus M, Gallagher HC, Burris TP, Egilmez NK. Oral IL-10 suppresses colon carcinogenesis via elimination of pathogenicCD4+ T-cells and induction of antitumor CD8+ T-cell activity. Oncoimmunology 2017;6:e1319027. [PMID: 28680752 DOI: 10.1080/2162402X.2017.1319027] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
334 Roberts JA, Gonzalez RS, Das S, Berlin J, Shi C. Expression of PD-1 and PD-L1 in poorly differentiated neuroendocrine carcinomas of the digestive system: a potential target for anti-PD-1/PD-L1 therapy. Hum Pathol 2017;70:49-54. [PMID: 29037958 DOI: 10.1016/j.humpath.2017.10.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
335 Ruffo E, Wu RC, Bruno TC, Workman CJ, Vignali DAA. Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor. Semin Immunol 2019;42:101305. [PMID: 31604537 DOI: 10.1016/j.smim.2019.101305] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 18.0] [Reference Citation Analysis]
336 Datta J, Berk E, Cintolo JA, Xu S, Roses RE, Czerniecki BJ. Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy. Front Immunol 2015;6:271. [PMID: 26082780 DOI: 10.3389/fimmu.2015.00271] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
337 Luchini C, Paolino G, Mattiolo P, Piredda ML, Cavaliere A, Gaule M, Melisi D, Salvia R, Malleo G, Shin JI, Cargnin S, Terrazzino S, Lawlor RT, Milella M, Scarpa A. KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities. J Exp Clin Cancer Res. 2020;39:227. [PMID: 33115526 DOI: 10.1186/s13046-020-01732-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
338 Kieler M, Scheithauer W, Zielinski CC, Chott A, Al-Mukhtar A, Prager G. Case report: impressive response to pembrolizumab in a patient with mismatch-repair deficient metastasized colorectal cancer and bulky disease. ESMO Open 2016;1:e000084. [PMID: 28255450 DOI: 10.1136/esmoopen-2016-000084] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
339 Wei XL, Wu QN, Chen DL, Zeng ZL, Lu JB, Liu ZX, Ju HQ, Ren C, Pan ZZ, Wang FH, Xu RH. The Clinical and Biomarker Association of Programmed Death Ligand 1 and its Spatial Heterogeneous Expression in Colorectal Cancer. J Cancer 2018;9:4325-33. [PMID: 30519336 DOI: 10.7150/jca.27735] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
340 Pérot P, Mullins CS, Naville M, Bressan C, Hühns M, Gock M, Kühn F, Volff JN, Trillet-Lenoir V, Linnebacher M, Mallet F. Expression of young HERV-H loci in the course of colorectal carcinoma and correlation with molecular subtypes. Oncotarget 2015;6:40095-111. [PMID: 26517682 DOI: 10.18632/oncotarget.5539] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
341 Brar G, Shah MA. The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma. Therap Adv Gastroenterol 2019;12:1756284819869767. [PMID: 31516556 DOI: 10.1177/1756284819869767] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
342 Zong S, Li C, Luo C, Zhao X, Liu C, Wang K, Jia W, Bai M, Yin M, Bao S, Guo J, Kang J, Duan T, Zhou Q. Dysregulated expression of IDO may cause unexplained recurrent spontaneous abortion through suppression of trophoblast cell proliferation and migration. Sci Rep 2016;6:19916. [PMID: 26814137 DOI: 10.1038/srep19916] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 6.3] [Reference Citation Analysis]
343 Donini C, D'Ambrosio L, Grignani G, Aglietta M, Sangiolo D. Next generation immune-checkpoints for cancer therapy. J Thorac Dis 2018;10:S1581-601. [PMID: 29951308 DOI: 10.21037/jtd.2018.02.79] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 8.0] [Reference Citation Analysis]
344 Bosisio FM, van den Oord JJ. Immunoplasticity in cutaneous melanoma: beyond pure morphology. Virchows Arch 2017;470:357-69. [PMID: 28054151 DOI: 10.1007/s00428-016-2058-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
345 Wakabayashi G, Lee YC, Luh F, Kuo CN, Chang WC, Yen Y. Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway. J Biomed Sci 2019;26:96. [PMID: 31801525 DOI: 10.1186/s12929-019-0588-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
346 Martin B, Märkl B. Immunologic Biomarkers and Biomarkers for Immunotherapies in Gastrointestinal Cancer. Visc Med 2019;35:3-10. [PMID: 31312644 DOI: 10.1159/000496565] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
347 Kosumi K, Masugi Y, Yang J, Qian ZR, Kim SA, Li W, Shi Y, da Silva A, Hamada T, Liu L, Gu M, Twombly TS, Cao Y, Barbie DA, Nosho K, Baba H, Garrett WS, Meyerhardt JA, Giovannucci EL, Chan AT, Fuchs CS, Ogino S, Nishihara R. Tumor SQSTM1 (p62) expression and T cells in colorectal cancer. Oncoimmunology 2017;6:e1284720. [PMID: 28405513 DOI: 10.1080/2162402X.2017.1284720] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
348 Nestarenkaite A, Fadhil W, Rasmusson A, Susanti S, Hadjimichael E, Laurinaviciene A, Ilyas M, Laurinavicius A. Immuno-Interface Score to Predict Outcome in Colorectal Cancer Independent of Microsatellite Instability Status. Cancers (Basel) 2020;12:E2902. [PMID: 33050344 DOI: 10.3390/cancers12102902] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
349 Park BV, Freeman ZT, Ghasemzadeh A, Chattergoon MA, Rutebemberwa A, Steigner J, Winter ME, Huynh TV, Sebald SM, Lee SJ, Pan F, Pardoll DM, Cox AL. TGFβ1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer. Cancer Discov 2016;6:1366-81. [PMID: 27683557 DOI: 10.1158/2159-8290.CD-15-1347] [Cited by in Crossref: 103] [Cited by in F6Publishing: 66] [Article Influence: 17.2] [Reference Citation Analysis]
350 Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried M, Penel N, Hansen AR, Piha-Paul SA, Doi T, Gao B, Chung HC, Lopez-Martin J, Bang YJ, Frommer RS, Shah M, Ghori R, Joe AK, Pruitt SK, Diaz LA Jr. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2020;38:1-10. [PMID: 31682550 DOI: 10.1200/jco.19.02105] [Cited by in Crossref: 433] [Cited by in F6Publishing: 256] [Article Influence: 144.3] [Reference Citation Analysis]
351 Ouyang FZ, Wu RQ, Wei Y, Liu RX, Yang D, Xiao X, Zheng L, Li B, Lao XM, Kuang DM. Dendritic cell-elicited B-cell activation fosters immune privilege via IL-10 signals in hepatocellular carcinoma. Nat Commun 2016;7:13453. [PMID: 27853178 DOI: 10.1038/ncomms13453] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 5.5] [Reference Citation Analysis]
352 Van Der Kraak L, Goel G, Ramanan K, Kaltenmeier C, Zhang L, Normolle DP, Freeman GJ, Tang D, Nason KS, Davison JM, Luketich JD, Dhupar R, Lotze MT. 5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers. J Immunother Cancer 2016;4:65. [PMID: 27777774 DOI: 10.1186/s40425-016-0163-8] [Cited by in Crossref: 52] [Cited by in F6Publishing: 54] [Article Influence: 8.7] [Reference Citation Analysis]
353 Kong P, Wang J, Song Z, Liu S, He W, Jiang C, Xie Q, Yang L, Xia X, Xia L. Circulating Lymphocytes, PD-L1 Expression on Tumor-infiltrating Lymphocytes, and Survival of Colorectal Cancer Patients with Different Mismatch Repair Gene Status. J Cancer 2019;10:1745-54. [PMID: 31205530 DOI: 10.7150/jca.25187] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
354 Chavez JA, Wei L, Suarez AA, Parwani AV, Li Z. Clinicopathologic characteristics, tumor infiltrating lymphocytes and programed cell death ligand-1 expression in 162 endometrial carcinomas with deficient mismatch repair function. Int J Gynecol Cancer 2019;29:113-8. [PMID: 30640692 DOI: 10.1136/ijgc-2018-000042] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
355 Du F, Liu Y. Predictive molecular markers for the treatment with immune checkpoint inhibitors in colorectal cancer. J Clin Lab Anal 2021;:e24141. [PMID: 34817097 DOI: 10.1002/jcla.24141] [Reference Citation Analysis]
356 Housseau F, Wu S, Wick EC, Fan H, Wu X, Llosa NJ, Smith KN, Tam A, Ganguly S, Wanyiri JW, Iyadorai T, Malik AA, Roslani AC, Vadivelu JS, Van Meerbeke S, Huso DL, Pardoll DM, Sears CL. Redundant Innate and Adaptive Sources of IL17 Production Drive Colon Tumorigenesis. Cancer Res 2016;76:2115-24. [PMID: 26880802 DOI: 10.1158/0008-5472.CAN-15-0749] [Cited by in Crossref: 76] [Cited by in F6Publishing: 45] [Article Influence: 12.7] [Reference Citation Analysis]
357 Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27:450-461. [PMID: 25858804 DOI: 10.1016/j.ccell.2015.03.001] [Cited by in Crossref: 2042] [Cited by in F6Publishing: 1942] [Article Influence: 291.7] [Reference Citation Analysis]
358 Mouw KW, Goldberg MS, Konstantinopoulos PA, D'Andrea AD. DNA Damage and Repair Biomarkers of Immunotherapy Response. Cancer Discov 2017;7:675-93. [PMID: 28630051 DOI: 10.1158/2159-8290.CD-17-0226] [Cited by in Crossref: 254] [Cited by in F6Publishing: 177] [Article Influence: 50.8] [Reference Citation Analysis]
359 El Bali M, Bakkach J, Bennani Mechita M. Colorectal Cancer: From Genetic Landscape to Targeted Therapy. J Oncol 2021;2021:9918116. [PMID: 34326875 DOI: 10.1155/2021/9918116] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
360 Lu C, Redd PS, Lee JR, Savage N, Liu K. The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells. Oncoimmunology 2016;5:e1247135. [PMID: 28123883 DOI: 10.1080/2162402X.2016.1247135] [Cited by in Crossref: 94] [Cited by in F6Publishing: 79] [Article Influence: 15.7] [Reference Citation Analysis]
361 Martin SZ, Wagner DC, Hörner N, Horst D, Lang H, Tagscherer KE, Roth W. Ex vivo tissue slice culture system to measure drug-response rates of hepatic metastatic colorectal cancer. BMC Cancer 2019;19:1030. [PMID: 31675944 DOI: 10.1186/s12885-019-6270-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
362 Sillo TO, Beggs AD, Morton DG, Middleton G. Mechanisms of immunogenicity in colorectal cancer. Br J Surg 2019;106:1283-97. [PMID: 31216061 DOI: 10.1002/bjs.11204] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
363 Masucci GV, Cesano A, Hawtin R, Janetzki S, Zhang J, Kirsch I, Dobbin KK, Alvarez J, Robbins PB, Selvan SR, Streicher HZ, Butterfield LH, Thurin M. Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation. J Immunother Cancer 2016;4:76. [PMID: 27895917 DOI: 10.1186/s40425-016-0178-1] [Cited by in Crossref: 101] [Cited by in F6Publishing: 92] [Article Influence: 16.8] [Reference Citation Analysis]
364 Wang Y, Ding Y, Deng Y, Zheng Y, Wang S. Role of myeloid-derived suppressor cells in the promotion and immunotherapy of colitis-associated cancer. J Immunother Cancer 2020;8:e000609. [PMID: 33051339 DOI: 10.1136/jitc-2020-000609] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
365 Kim JH, Kim SY, Baek JY, Cha YJ, Ahn JB, Kim HS, Lee KW, Kim JW, Kim TY, Chang WJ, Park JO, Kim J, Kim JE, Hong YS, Kim YH, Kim TW. A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair-Deficient/Microsatellite Instability-High or POLE-Mutated Metastatic or Unresectable Colorectal Cancer. Cancer Res Treat 2020;52:1135-44. [PMID: 32340084 DOI: 10.4143/crt.2020.218] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
366 Zaborowski AM, Winter DC, Lynch L. The therapeutic and prognostic implications of immunobiology in colorectal cancer: a review. Br J Cancer 2021. [PMID: 34302062 DOI: 10.1038/s41416-021-01475-x] [Reference Citation Analysis]
367 Farolfi A, Gurioli G, Fugazzola P, Burgio SL, Casanova C, Ravaglia G, Altavilla A, Costantini M, Amadori A, Framarini M, Ansaloni L, De Giorgi U. Immune System and DNA Repair Defects in Ovarian Cancer: Implications for Locoregional Approaches. Int J Mol Sci 2019;20:E2569. [PMID: 31130614 DOI: 10.3390/ijms20102569] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
368 Sui Q, Liu D, Jiang W, Tang J, Kong L, Han K, Liao L, Li Y, Ou Q, Xiao B, Liu G, Ling Y, Chen J, Liu Z, Zuo Z, Pan Z, Zhou P, Zheng J, Ding PR. Dickkopf 1 impairs the tumor response to PD-1 blockade by inactivating CD8+ T cells in deficient mismatch repair colorectal cancer. J Immunother Cancer 2021;9:e001498. [PMID: 33782107 DOI: 10.1136/jitc-2020-001498] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
369 Stone ML, Beatty GL. Cellular determinants and therapeutic implications of inflammation in pancreatic cancer. Pharmacol Ther. 2019;201:202-213. [PMID: 31158393 DOI: 10.1016/j.pharmthera.2019.05.012] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 7.7] [Reference Citation Analysis]
370 Ruan H, Leibowitz BJ, Zhang L, Yu J. Immunogenic cell death in colon cancer prevention and therapy. Mol Carcinog 2020;59:783-93. [PMID: 32215970 DOI: 10.1002/mc.23183] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
371 Lu C, Yang D, Klement JD, Oh IK, Savage NM, Waller JL, Colby AH, Grinstaff MW, Oberlies NH, Pearce CJ, Xie Z, Kulp SK, Coss CC, Phelps MA, Albers T, Lebedyeva IO, Liu K. SUV39H1 Represses the Expression of Cytotoxic T-Lymphocyte Effector Genes to Promote Colon Tumor Immune Evasion. Cancer Immunol Res 2019;7:414-27. [PMID: 30610059 DOI: 10.1158/2326-6066.CIR-18-0126] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
372 Wu J, Zhao Y, Zhang J, Wu Q, Wang W. Development and validation of an immune-related gene pairs signature in colorectal cancer. Oncoimmunology 2019;8:1596715. [PMID: 31143520 DOI: 10.1080/2162402X.2019.1596715] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 12.3] [Reference Citation Analysis]
373 Willis JA, Reyes-Uribe L, Chang K, Lipkin SM, Vilar E. Immune Activation in Mismatch Repair-Deficient Carcinogenesis: More Than Just Mutational Rate. Clin Cancer Res 2020;26:11-7. [PMID: 31383734 DOI: 10.1158/1078-0432.CCR-18-0856] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
374 Verdaguer H, Saurí T, Macarulla T. Predictive and prognostic biomarkers in personalized gastrointestinal cancer treatment. J Gastrointest Oncol 2017;8:405-17. [PMID: 28736628 DOI: 10.21037/jgo.2016.11.15] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
375 Alvi MA, Loughrey MB, Dunne P, McQuaid S, Turkington R, Fuchs MA, McGready C, Bingham V, Pang B, Moore W, Maxwell P, Lawler M, James JA, Murray GI, Wilson RH, Salto-Tellez M. Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies. Br J Cancer. 2017;117:203-209. [PMID: 28595259 DOI: 10.1038/bjc.2017.168] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
376 Masugi Y, Nishihara R, Hamada T, Song M, da Silva A, Kosumi K, Gu M, Shi Y, Li W, Liu L, Nevo D, Inamura K, Cao Y, Liao X, Nosho K, Chan AT, Giannakis M, Bass AJ, Hodi FS, Freeman GJ, Rodig SJ, Fuchs CS, Qian ZR, Nowak JA, Ogino S. Tumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal Cancer. Cancer Immunol Res 2017;5:1046-55. [PMID: 29038297 DOI: 10.1158/2326-6066.CIR-17-0122] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
377 Mittica G, Genta S, Aglietta M, Valabrega G. Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer? Int J Mol Sci. 2016;17. [PMID: 27447625 DOI: 10.3390/ijms17071169] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 5.8] [Reference Citation Analysis]
378 Wood SM, Gill AJ, Brodsky AS, Lu S, Friedman K, Karashchuk G, Lombardo K, Yang D, Resnick MB. Fatty acid-binding protein 1 is preferentially lost in microsatellite instable colorectal carcinomas and is immune modulated via the interferon γ pathway. Mod Pathol 2017;30:123-33. [PMID: 27687006 DOI: 10.1038/modpathol.2016.170] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
379 Hermel DJ, Sigal D. The Emerging Role of Checkpoint Inhibition in Microsatellite Stable Colorectal Cancer. J Pers Med. 2019;9. [PMID: 30654522 DOI: 10.3390/jpm9010005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
380 Valentini AM, Di Pinto F, Coletta S, Guerra V, Armentano R, Caruso ML. Tumor microenvironment immune types in gastric cancer are associated with mismatch repair however, not HER2 status. Oncol Lett 2019;18:1775-85. [PMID: 31423245 DOI: 10.3892/ol.2019.10513] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
381 Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 2016;16:275-87. [PMID: 27079802 DOI: 10.1038/nrc.2016.36] [Cited by in Crossref: 1185] [Cited by in F6Publishing: 1154] [Article Influence: 197.5] [Reference Citation Analysis]
382 Loeser H, Kraemer M, Gebauer F, Bruns C, Schröder W, Zander T, Alakus H, Hoelscher A, Buettner R, Lohneis P, Quaas A. Indoleamine 2,3-Dioxygenase (IDO) Expression Is an Independent Prognostic Marker in Esophageal Adenocarcinoma. J Immunol Res 2020;2020:2862647. [PMID: 33029538 DOI: 10.1155/2020/2862647] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
383 Gao D, Herman JG, Guo M. The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer. Oncotarget 2016;7:37331-46. [PMID: 26967246 DOI: 10.18632/oncotarget.7949] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 12.8] [Reference Citation Analysis]
384 West NR, McCuaig S, Franchini F, Powrie F. Emerging cytokine networks in colorectal cancer. Nat Rev Immunol. 2015;15:615-629. [PMID: 26358393 DOI: 10.1038/nri3896] [Cited by in Crossref: 184] [Cited by in F6Publishing: 176] [Article Influence: 26.3] [Reference Citation Analysis]
385 Yunoki K, Yano T, Yoshimitsu M, Oshita K, Kubota T, Ishida M, Satoh D, Choda Y, Nakano K, Shirakawa Y, Matsukawa H, Idani H, Shiozaki S, Okajima M. Cutaneous metastasis of cecum cancer with MSI-high and BRAFV600E mutation: a case report. Surg Case Rep 2021;7:185. [PMID: 34406516 DOI: 10.1186/s40792-021-01265-w] [Reference Citation Analysis]
386 Bonneville R, Krook MA, Chen HZ, Smith A, Samorodnitsky E, Wing MR, Reeser JW, Roychowdhury S. Detection of Microsatellite Instability Biomarkers via Next-Generation Sequencing. Methods Mol Biol 2020;2055:119-32. [PMID: 31502149 DOI: 10.1007/978-1-4939-9773-2_5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
387 Hamada T, Zhang X, Mima K, Bullman S, Sukawa Y, Nowak JA, Kosumi K, Masugi Y, Twombly TS, Cao Y, Song M, Liu L, da Silva A, Shi Y, Gu M, Li W, Koh H, Nosho K, Inamura K, Keum N, Wu K, Meyerhardt JA, Kostic AD, Huttenhower C, Garrett WS, Meyerson M, Giovannucci EL, Chan AT, Fuchs CS, Nishihara R, Giannakis M, Ogino S. Fusobacterium nucleatum in Colorectal Cancer Relates to Immune Response Differentially by Tumor Microsatellite Instability Status. Cancer Immunol Res 2018;6:1327-36. [PMID: 30228205 DOI: 10.1158/2326-6066.CIR-18-0174] [Cited by in Crossref: 51] [Cited by in F6Publishing: 40] [Article Influence: 12.8] [Reference Citation Analysis]
388 Yan X, Zhang S, Deng Y, Wang P, Hou Q, Xu H. Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences. Front Pharmacol 2018;9:1050. [PMID: 30294272 DOI: 10.3389/fphar.2018.01050] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
389 Valentini AM, Di Pinto F, Cariola F, Guerra V, Giannelli G, Caruso ML, Pirrelli M. PD-L1 expression in colorectal cancer defines three subsets of tumor immune microenvironments. Oncotarget 2018;9:8584-96. [PMID: 29492219 DOI: 10.18632/oncotarget.24196] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
390 Sumransub N, Vantanasiri K, Prakash A, Lou E. Advances and new frontiers for immunotherapy in colorectal cancer: Setting the stage for neoadjuvant success? Mol Ther Oncolytics 2021;22:1-12. [PMID: 34307839 DOI: 10.1016/j.omto.2021.05.001] [Reference Citation Analysis]
391 Selby MJ, Engelhardt JJ, Johnston RJ, Lu LS, Han M, Thudium K, Yao D, Quigley M, Valle J, Wang C, Chen B, Cardarelli PM, Blanset D, Korman AJ. Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology. PLoS One 2016;11:e0161779. [PMID: 27610613 DOI: 10.1371/journal.pone.0161779] [Cited by in Crossref: 95] [Cited by in F6Publishing: 95] [Article Influence: 15.8] [Reference Citation Analysis]
392 Phung TN, Lenkiewicz E, Malasi S, Sharma A, Anderson KS, Wilson MA, Pockaj BA, Barrett MT. Unique genomic and neoepitope landscapes across tumors: a study across time, tissues, and space within a single lynch syndrome patient. Sci Rep 2020;10:12190. [PMID: 32699259 DOI: 10.1038/s41598-020-68939-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
393 Roth MT, Das S. Pembrolizumab in unresectable or metastatic MSI-high colorectal cancer: safety and efficacy. Expert Rev Anticancer Ther. 2021;21:229-238. [PMID: 33183114 DOI: 10.1080/14737140.2021.1851201] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
394 Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19:133-150. [PMID: 30755690 DOI: 10.1038/s41568-019-0116-x] [Cited by in Crossref: 726] [Cited by in F6Publishing: 703] [Article Influence: 242.0] [Reference Citation Analysis]
395 Goel G, Sun W. Advances in the management of gastrointestinal cancers--an upcoming role of immune checkpoint blockade. J Hematol Oncol 2015;8:86. [PMID: 26174086 DOI: 10.1186/s13045-015-0185-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
396 Jing W, Li M, Zhang Y, Teng F, Han A, Kong L, Zhu H. PD-1/PD-L1 blockades in non-small-cell lung cancer therapy. Onco Targets Ther 2016;9:489-502. [PMID: 26889087 DOI: 10.2147/OTT.S94993] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
397 Moufarrij S, Dandapani M, Arthofer E, Gomez S, Srivastava A, Lopez-Acevedo M, Villagra A, Chiappinelli KB. Epigenetic therapy for ovarian cancer: promise and progress. Clin Epigenetics 2019;11:7. [PMID: 30646939 DOI: 10.1186/s13148-018-0602-0] [Cited by in Crossref: 62] [Cited by in F6Publishing: 60] [Article Influence: 20.7] [Reference Citation Analysis]
398 Song M, Ou FS, Zemla TJ, Hull MA, Shi Q, Limburg PJ, Alberts SR, Sinicrope FA, Giovannucci EL, Van Blarigan EL, Meyerhardt JA, Chan AT. Marine omega-3 fatty acid intake and survival of stage III colon cancer according to tumor molecular markers in NCCTG Phase III trial N0147 (Alliance). Int J Cancer 2019;145:380-9. [PMID: 30623420 DOI: 10.1002/ijc.32113] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
399 Kong P, Wu R, Lan Y, He W, Yang C, Yin C, Yang Q, Jiang C, Xu D, Xia L. Association between Mismatch-repair Genetic variation and the Risk of Multiple Primary Cancers: A Meta-Analysis. J Cancer 2017;8:3296-308. [PMID: 29158803 DOI: 10.7150/jca.19810] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
400 Villéger R, Lopès A, Veziant J, Gagnière J, Barnich N, Billard E, Boucher D, Bonnet M. Microbial markers in colorectal cancer detection and/or prognosis. World J Gastroenterol 2018; 24(22): 2327-2347 [PMID: 29904241 DOI: 10.3748/wjg.v24.i22.2327] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 36] [Article Influence: 11.0] [Reference Citation Analysis]
401 Kambayashi Y, Fujimura T, Hidaka T, Aiba S. Biomarkers for Predicting Efficacies of Anti-PD1 Antibodies. Front Med (Lausanne) 2019;6:174. [PMID: 31417907 DOI: 10.3389/fmed.2019.00174] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
402 Bersanelli M, Buti S. From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis. World J Clin Oncol 2017; 8(1): 37-53 [PMID: 28246584 DOI: 10.5306/wjco.v8.i1.37] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 33] [Article Influence: 6.4] [Reference Citation Analysis]
403 Arora SP, Mahalingam D. Immunotherapy in colorectal cancer: for the select few or all? J Gastrointest Oncol. 2018;9:170-179. [PMID: 29564183 DOI: 10.21037/jgo.2017.06.10] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
404 Šmahel M. PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression. Int J Mol Sci 2017;18:E1331. [PMID: 28635644 DOI: 10.3390/ijms18061331] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 7.4] [Reference Citation Analysis]
405 Liu S, Gӧnen M, Stadler ZK, Weiser MR, Hechtman JF, Vakiani E, Wang T, Vyas M, Joneja U, Al-Bayati M, Segal NH, Smith JJ, King S, Guercio S, Ntiamoah P, Markowitz AJ, Zhang L, Cercek A, Garcia-Aguilar J, Saltz LB, Diaz LA, Klimstra DS, Shia J. Cellular localization of PD-L1 expression in mismatch-repair-deficient and proficient colorectal carcinomas. Mod Pathol 2019;32:110-21. [PMID: 30166615 DOI: 10.1038/s41379-018-0114-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
406 Yamashita K, Iwatsuki M, Ajani JA, Baba H. Programmed death ligand-1 expression in gastrointestinal cancer: Clinical significance and future challenges. Ann Gastroenterol Surg 2020;4:369-78. [PMID: 32724880 DOI: 10.1002/ags3.12348] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
407 Fletcher R, Wang YJ, Schoen RE, Finn OJ, Yu J, Zhang L. Colorectal cancer prevention: Immune modulation taking the stage. Biochim Biophys Acta Rev Cancer 2018;1869:138-48. [PMID: 29391185 DOI: 10.1016/j.bbcan.2017.12.002] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 6.8] [Reference Citation Analysis]
408 Lee V, Murphy A, Le DT, Diaz LA Jr. Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade. Oncologist. 2016;21:1200-1211. [PMID: 27412392 DOI: 10.1634/theoncologist.2016-0046] [Cited by in Crossref: 116] [Cited by in F6Publishing: 113] [Article Influence: 19.3] [Reference Citation Analysis]
409 Puca E, Schmitt-Koopmann C, Furter M, Murer P, Probst P, Dihr M, Bajic D, Neri D. The targeted delivery of interleukin-12 to the carcinoembryonic antigen increases the intratumoral density of NK and CD8+ T cell in an immunocompetent mouse model of colorectal cancer. J Gastrointest Oncol 2020;11:803-11. [PMID: 32953162 DOI: 10.21037/jgo.2020.04.02] [Reference Citation Analysis]
410 Lipson EJ, Forde PM, Hammers HJ, Emens LA, Taube JM, Topalian SL. Antagonists of PD-1 and PD-L1 in Cancer Treatment. Semin Oncol. 2015;42:587-600. [PMID: 26320063 DOI: 10.1053/j.seminoncol.2015.05.013] [Cited by in Crossref: 168] [Cited by in F6Publishing: 164] [Article Influence: 24.0] [Reference Citation Analysis]
411 Wagner S, Mullins CS, Linnebacher M. Colorectal cancer vaccines: Tumor-associated antigens vs neoantigens. World J Gastroenterol 2018; 24(48): 5418-5432 [PMID: 30622371 DOI: 10.3748/wjg.v24.i48.5418] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 29] [Article Influence: 7.8] [Reference Citation Analysis]
412 Herting CJ, Farren MR, Tong Y, Liu Z, O'Neil B, Bekaii-Saab T, Noonan A, McQuinn C, Mace TA, Shaib W, Wu C, El-Rayes BF, Shahda S, Lesinski GB. A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186. Cancer Immunol Immunother 2021. [PMID: 34160684 DOI: 10.1007/s00262-021-02986-5] [Reference Citation Analysis]
413 Fakih M, Ouyang C, Wang C, Tu TY, Gozo MC, Cho M, Sy M, Longmate JA, Lee PP. Immune overdrive signature in colorectal tumor subset predicts poor clinical outcome. J Clin Invest 2019;129:4464-76. [PMID: 31524634 DOI: 10.1172/JCI127046] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 13.0] [Reference Citation Analysis]
414 Amodio V, Mauri G, Reilly NM, Sartore-Bianchi A, Siena S, Bardelli A, Germano G. Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers. Cancers (Basel) 2021;13:2638. [PMID: 34072037 DOI: 10.3390/cancers13112638] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
415 Mima K, Sukawa Y, Nishihara R, Qian ZR, Yamauchi M, Inamura K, Kim SA, Masuda A, Nowak JA, Nosho K, Kostic AD, Giannakis M, Watanabe H, Bullman S, Milner DA, Harris CC, Giovannucci E, Garraway LA, Freeman GJ, Dranoff G, Chan AT, Garrett WS, Huttenhower C, Fuchs CS, Ogino S. Fusobacterium nucleatum and T Cells in Colorectal Carcinoma. JAMA Oncol. 2015;1:653-661. [PMID: 26181352 DOI: 10.1001/jamaoncol.2015.1377] [Cited by in Crossref: 264] [Cited by in F6Publishing: 254] [Article Influence: 44.0] [Reference Citation Analysis]
416 Shembrey C, Huntington ND, Hollande F. Impact of Tumor and Immunological Heterogeneity on the Anti-Cancer Immune Response. Cancers (Basel) 2019;11:E1217. [PMID: 31438563 DOI: 10.3390/cancers11091217] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
417 Kim E, Kim K, Kim SH, Han SW, Kim TY, Jeong SY, Park KJ, Koh J, Kang GH, Chie EK. Impact of Mucin Proportion in the Pretreatment MRI on the Outcomes of Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy. Cancer Res Treat 2019;51:1188-97. [PMID: 30590006 DOI: 10.4143/crt.2018.434] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
418 Huyghe N, Baldin P, Van den Eynde M. Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours? Gastroenterol Rep (Oxf) 2020;8:11-24. [PMID: 32104582 DOI: 10.1093/gastro/goz061] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 8.7] [Reference Citation Analysis]
419 Hiraoka N, Ino Y, Yamazaki-Itoh R. Tertiary Lymphoid Organs in Cancer Tissues. Front Immunol 2016;7:244. [PMID: 27446075 DOI: 10.3389/fimmu.2016.00244] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 8.3] [Reference Citation Analysis]
420 Shen H, Yang ES, Conry M, Fiveash J, Contreras C, Bonner JA, Shi LZ. Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies. Genes Dis 2019;6:232-46. [PMID: 32042863 DOI: 10.1016/j.gendis.2019.06.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
421 Dunne MR, Ryan C, Nolan B, Tosetto M, Geraghty R, Winter DC, O'Connell PR, Hyland JM, Doherty GA, Sheahan K, Ryan EJ, Fletcher JM. Enrichment of Inflammatory IL-17 and TNF-α Secreting CD4(+) T Cells within Colorectal Tumors despite the Presence of Elevated CD39(+) T Regulatory Cells and Increased Expression of the Immune Checkpoint Molecule, PD-1. Front Oncol 2016;6:50. [PMID: 27014625 DOI: 10.3389/fonc.2016.00050] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
422 Zaravinos A, Roufas C, Nagara M, de Lucas Moreno B, Oblovatskaya M, Efstathiades C, Dimopoulos C, Ayiomamitis GD. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer. J Exp Clin Cancer Res 2019;38:364. [PMID: 31429779 DOI: 10.1186/s13046-019-1372-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
423 Angelova M, Charoentong P, Hackl H, Trajanoski Z. The colorectal cancer immune paradox revisited. Oncoimmunology 2016;5:e1078058. [PMID: 27057454 DOI: 10.1080/2162402X.2015.1078058] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
424 Sato H, Jeggo PA, Shibata A. Regulation of programmed death-ligand 1 expression in response to DNA damage in cancer cells: Implications for precision medicine. Cancer Sci 2019;110:3415-23. [PMID: 31513320 DOI: 10.1111/cas.14197] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
425 Passardi A, Canale M, Valgiusti M, Ulivi P. Immune Checkpoints as a Target for Colorectal Cancer Treatment. Int J Mol Sci. 2017;18:1324. [PMID: 28635639 DOI: 10.3390/ijms18061324] [Cited by in Crossref: 62] [Cited by in F6Publishing: 63] [Article Influence: 12.4] [Reference Citation Analysis]
426 Liu J, Geng X, Hou J, Wu G. New insights into M1/M2 macrophages: key modulators in cancer progression. Cancer Cell Int 2021;21:389. [PMID: 34289846 DOI: 10.1186/s12935-021-02089-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
427 Choi J, Manzano A, Dong W, Bellone S, Bonazzoli E, Zammataro L, Yao X, Deshpande A, Zaidi S, Guglielmi A, Gnutti B, Nagarkatti N, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Jeong K, Zhao S, Buza N, Hui P, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Odicino F, Pecorelli S, Ardighieri L, Bilguvar K, Quick CM, Silasi DA, Huang GS, Andikyan V, Clark M, Ratner E, Azodi M, Imielinski M, Schwartz PE, Alexandrov LB, Lifton RP, Schlessinger J, Santin AD. Integrated mutational landscape analysis of uterine leiomyosarcomas. Proc Natl Acad Sci U S A 2021;118:e2025182118. [PMID: 33876771 DOI: 10.1073/pnas.2025182118] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
428 Ryan ÉJ, Creavin B, Sheahan K. Delivery of Personalized Care for Locally Advanced Rectal Cancer: Incorporating Pathological, Molecular Genetic, and Immunological Biomarkers Into the Multimodal Paradigm. Front Oncol 2020;10:1369. [PMID: 32923389 DOI: 10.3389/fonc.2020.01369] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
429 Mudd TW Jr, Lu C, Klement JD, Liu K. MS4A1 expression and function in T cells in the colorectal cancer tumor microenvironment. Cell Immunol 2021;360:104260. [PMID: 33352466 DOI: 10.1016/j.cellimm.2020.104260] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
430 Terranova-Barberio M, Thomas S, Munster PN. Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors. Immunotherapy 2016;8:705-19. [PMID: 27197539 DOI: 10.2217/imt-2016-0014] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 7.8] [Reference Citation Analysis]
431 Andrews LP, Marciscano AE, Drake CG, Vignali DA. LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev 2017;276:80-96. [PMID: 28258692 DOI: 10.1111/imr.12519] [Cited by in Crossref: 302] [Cited by in F6Publishing: 303] [Article Influence: 60.4] [Reference Citation Analysis]
432 Mima K, Nishihara R, Nowak JA, Kim SA, Song M, Inamura K, Sukawa Y, Masuda A, Yang J, Dou R, Nosho K, Baba H, Giovannucci EL, Bowden M, Loda M, Giannakis M, Bass AJ, Dranoff G, Freeman GJ, Chan AT, Fuchs CS, Qian ZR, Ogino S. MicroRNA MIR21 and T Cells in Colorectal Cancer. Cancer Immunol Res 2016;4:33-40. [PMID: 26419959 DOI: 10.1158/2326-6066.CIR-15-0084] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.1] [Reference Citation Analysis]
433 Germann M, Zangger N, Sauvain MO, Sempoux C, Bowler AD, Wirapati P, Kandalaft LE, Delorenzi M, Tejpar S, Coukos G, Radtke F. Neutrophils suppress tumor-infiltrating T cells in colon cancer via matrix metalloproteinase-mediated activation of TGFβ. EMBO Mol Med 2020;12:e10681. [PMID: 31793740 DOI: 10.15252/emmm.201910681] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 10.3] [Reference Citation Analysis]
434 Zhou G, Noordam L, Sprengers D, Doukas M, Boor PPC, van Beek AA, Erkens R, Mancham S, Grünhagen D, Menon AG, Lange JF, Burger PJWA, Brandt A, Galjart B, Verhoef C, Kwekkeboom J, Bruno MJ. Blockade of LAG3 enhances responses of tumor-infiltrating T cells in mismatch repair-proficient liver metastases of colorectal cancer. Oncoimmunology 2018;7:e1448332. [PMID: 29900067 DOI: 10.1080/2162402X.2018.1448332] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
435 Zhu G, Ren D, Lei X, Shi R, Zhu S, Zhou N, Zu L, Mello RA, Chen J, Xu S. Mutations Associated with No Durable Clinical Benefit to Immune Checkpoint Blockade in Non-S-Cell Lung Cancer. Cancers (Basel) 2021;13:1397. [PMID: 33808631 DOI: 10.3390/cancers13061397] [Reference Citation Analysis]
436 Cohen R, Svrcek M, Dreyer C, Cervera P, Duval A, Pocard M, Fléjou JF, de Gramont A, André T. New Therapeutic Opportunities Based on DNA Mismatch Repair and BRAF Status in Metastatic Colorectal Cancer. Curr Oncol Rep 2016;18:18. [PMID: 26861657 DOI: 10.1007/s11912-016-0504-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
437 Li J, Wang B, Luo Y, Bian Y, Wang R. Effect of artemisinin and neurectomy of pterygoid canal in ovalbumin-induced allergic rhinitis mouse model. Allergy Asthma Clin Immunol 2018;14:22. [PMID: 29991950 DOI: 10.1186/s13223-018-0249-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
438 Asano T, Ohishi T, Takei J, Nakamura T, Nanamiya R, Hosono H, Tanaka T, Sano M, Harada H, Kawada M, Kaneko MK, Kato Y. Anti‑HER3 monoclonal antibody exerts antitumor activity in a mouse model of colorectal adenocarcinoma. Oncol Rep 2021;46:173. [PMID: 34184091 DOI: 10.3892/or.2021.8124] [Reference Citation Analysis]
439 Wu W, Liu Y, Zeng S, Han Y, Shen H. Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-γ signaling and tumor-infiltrating lymphocytes. J Hematol Oncol 2021;14:160. [PMID: 34620200 DOI: 10.1186/s13045-021-01166-3] [Reference Citation Analysis]
440 Huang CY, Chiang SF, Ke TW, Chen TW, You YS, Chen WT, Chao KSC. Clinical significance of programmed death 1 ligand-1 (CD274/PD-L1) and intra-tumoral CD8+ T-cell infiltration in stage II-III colorectal cancer. Sci Rep 2018;8:15658. [PMID: 30353144 DOI: 10.1038/s41598-018-33927-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
441 Li X, Zhang Q, Chen G, Luo D. Multi-Omics Analysis Showed the Clinical Value of Gene Signatures of C1QC+ and SPP1+ TAMs in Cervical Cancer. Front Immunol 2021;12:694801. [PMID: 34295336 DOI: 10.3389/fimmu.2021.694801] [Reference Citation Analysis]
442 Roxburgh CS, Shia J, Vakiani E, Daniel T, Weiser MR. Potential immune priming of the tumor microenvironment with FOLFOX chemotherapy in locally advanced rectal cancer. Oncoimmunology 2018;7:e1435227. [PMID: 29872576 DOI: 10.1080/2162402X.2018.1435227] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
443 O'Konek JJ, Ambrosino E, Bloom AC, Pasquet L, Massilamany C, Xia Z, Terabe M, Berzofsky JA. Differential Regulation of T-cell mediated anti-tumor memory and cross-protection against the same tumor in lungs versus skin. Oncoimmunology 2018;7:e1439305. [PMID: 29900040 DOI: 10.1080/2162402X.2018.1439305] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
444 Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, Wong F, Azad NS, Rucki AA, Laheru D, Donehower R, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Greten TF, Duffy AG, Ciombor KK, Eyring AD, Lam BH, Joe A, Kang SP, Holdhoff M, Danilova L, Cope L, Meyer C, Zhou S, Goldberg RM, Armstrong DK, Bever KM, Fader AN, Taube J, Housseau F, Spetzler D, Xiao N, Pardoll DM, Papadopoulos N, Kinzler KW, Eshleman JR, Vogelstein B, Anders RA, Diaz LA Jr. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409-413. [PMID: 28596308 DOI: 10.1126/science.aan6733] [Cited by in Crossref: 2579] [Cited by in F6Publishing: 2457] [Article Influence: 515.8] [Reference Citation Analysis]
445 Mola S, Pandolfo C, Sica A, Porta C. The Macrophages-Microbiota Interplay in Colorectal Cancer (CRC)-Related Inflammation: Prognostic and Therapeutic Significance. Int J Mol Sci 2020;21:E6866. [PMID: 32962159 DOI: 10.3390/ijms21186866] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
446 Mohammed A, Dashwood RH, Dickinson S, Disis ML, Jaffee EM, Johnson BD, Khleif SN, Pollak MN, Schlom J, Shoemaker RH, Stanton SE, Wondrak GT, You M, Zhu H, Miller MS. Translational Advances in Cancer Prevention Agent Development (TACPAD) Virtual Workshop on Immunomodulatory Agents: Report. J Cancer Prev 2021;26:309-17. [PMID: 35047458 DOI: 10.15430/JCP.2021.26.4.309] [Reference Citation Analysis]
447 Zhou XM, Li WQ, Wu YH, Han L, Cao XG, Yang XM, Wang HF, Zhao WS, Zhai WJ, Qi YM, Gao YF. Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth in vivo by Suppressing the Function of NK and CD8+ T Cells. Front Immunol 2018;9:2821. [PMID: 30555485 DOI: 10.3389/fimmu.2018.02821] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 9.3] [Reference Citation Analysis]
448 Zhao P, Li L, Jiang X, Li Q. Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy. J Hematol Oncol 2019;12:54. [PMID: 31151482 DOI: 10.1186/s13045-019-0738-1] [Cited by in Crossref: 118] [Cited by in F6Publishing: 113] [Article Influence: 39.3] [Reference Citation Analysis]
449 Zhang Y, Zhang L, Sun H, Liu Y, Xu J, Huang H, Fu J, Zhang D, Tian T, Zhao Y, Wang G. Inhibitory immune checkpoints PDCD-1 and LAG-3 hypermethylation may reduce the risk of colorectal cancer. Mol Med 2021;27:114. [PMID: 34544358 DOI: 10.1186/s10020-021-00373-5] [Reference Citation Analysis]
450 Arora S, Velichinskii R, Lesh RW, Ali U, Kubiak M, Bansal P, Borghaei H, Edelman MJ, Boumber Y. Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors. Adv Ther 2019;36:2638-78. [PMID: 31410780 DOI: 10.1007/s12325-019-01051-z] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 18.7] [Reference Citation Analysis]
451 Duan X, Chan C, Han W, Guo N, Weichselbaum RR, Lin W. Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors. Nat Commun 2019;10:1899. [PMID: 31015397 DOI: 10.1038/s41467-019-09221-x] [Cited by in Crossref: 87] [Cited by in F6Publishing: 87] [Article Influence: 29.0] [Reference Citation Analysis]
452 Franke AJ, Skelton WP, Starr JS, Parekh H, Lee JJ, Overman MJ, Allegra C, George TJ. Immunotherapy for Colorectal Cancer: A Review of Current and Novel Therapeutic Approaches. J Natl Cancer Inst 2019;111:1131-41. [PMID: 31322663 DOI: 10.1093/jnci/djz093] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 17.5] [Reference Citation Analysis]
453 Kamal Y, Schmit SL, Frost HR, Amos CI. The tumor microenvironment of colorectal cancer metastases: opportunities in cancer immunotherapy. Immunotherapy 2020;12:1083-100. [PMID: 32787587 DOI: 10.2217/imt-2020-0026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
454 Bottai G, Raschioni C, Losurdo A, Di Tommaso L, Tinterri C, Torrisi R, Reis-Filho JS, Roncalli M, Sotiriou C, Santoro A, Mantovani A, Loi S, Santarpia L. An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers. Breast Cancer Res 2016;18:121. [PMID: 27912781 DOI: 10.1186/s13058-016-0783-4] [Cited by in Crossref: 58] [Cited by in F6Publishing: 61] [Article Influence: 9.7] [Reference Citation Analysis]
455 Tintelnot J, Stein A. Immunotherapy in colorectal cancer: Available clinical evidence, challenges and novel approaches. World J Gastroenterol 2019; 25(29): 3920-3928 [PMID: 31413527 DOI: 10.3748/wjg.v25.i29.3920] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
456 Solinas C, Migliori E, De Silva P, Willard-Gallo K. LAG3: The Biological Processes That Motivate Targeting This Immune Checkpoint Molecule in Human Cancer. Cancers (Basel) 2019;11:E1213. [PMID: 31434339 DOI: 10.3390/cancers11081213] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 11.7] [Reference Citation Analysis]
457 Nowak JA, Yurgelun MB, Bruce JL, Rojas-Rudilla V, Hall DL, Shivdasani P, Garcia EP, Agoston AT, Srivastava A, Ogino S, Kuo FC, Lindeman NI, Dong F. Detection of Mismatch Repair Deficiency and Microsatellite Instability in Colorectal Adenocarcinoma by Targeted Next-Generation Sequencing. J Mol Diagn 2017;19:84-91. [PMID: 27863258 DOI: 10.1016/j.jmoldx.2016.07.010] [Cited by in Crossref: 78] [Cited by in F6Publishing: 75] [Article Influence: 13.0] [Reference Citation Analysis]
458 Di Bartolomeo M, Morano F, Raimondi A, Miceli R, Corallo S, Tamborini E, Perrone F, Antista M, Niger M, Pellegrinelli A, Randon G, Pagani F, Martinetti A, Fucà G, Pietrantonio F; ITACA-S study group. Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial. Oncologist 2020;25:e460-8. [PMID: 32162808 DOI: 10.1634/theoncologist.2019-0471] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
459 Pan W, Zhao J, Zhang S, Chen X, Liang W, Li Q. Towards exertion of immunotherapeutics in the treatment of colorectal cancer; adverse sides, challenges, and future directions. Int Immunopharmacol 2021;101:108337. [PMID: 34775366 DOI: 10.1016/j.intimp.2021.108337] [Reference Citation Analysis]
460 Majumder S, Shah R, Elias J, Manoharan M, Shah P, Kumari A, Chakraborty P, Kode V, Mistry Y, Coral K, Mittal B, Sm SM, Mahadevan L, Gupta R, Chaudhuri A, Khanna-Gupta A. A cancer vaccine approach for personalized treatment of Lynch Syndrome. Sci Rep 2018;8:12122. [PMID: 30108227 DOI: 10.1038/s41598-018-30466-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
461 Liu M, Kalbasi A, Beatty GL. Functio Laesa: Cancer Inflammation and Therapeutic Resistance. J Oncol Pract 2017;13:173-80. [PMID: 28282278 DOI: 10.1200/JOP.2016.020347] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
462 Voutsadakis IA. High Tumor Mutation Burden and Other Immunotherapy Response Predictors in Breast Cancers: Associations and Therapeutic Opportunities. Target Oncol 2020;15:127-38. [PMID: 31741177 DOI: 10.1007/s11523-019-00689-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
463 Glazko G, Zybailov B, Emmert-Streib F, Baranova A, Rahmatallah Y. Proteome-transcriptome alignment of molecular portraits achieved by self-contained gene set analysis: Consensus colon cancer subtypes case study. PLoS One 2019;14:e0221444. [PMID: 31437237 DOI: 10.1371/journal.pone.0221444] [Reference Citation Analysis]
464 Hosseini S, Nguyen N, Mohammadianpanah M, Mirzaei S, Bananzadeh AM. Predictive Significance of Mucinous Histology on Pathologic Complete Response Rate Following Capecitabine-Based Neoadjuvant Chemoradiation in Rectal Cancer: a Comparative Study. J Gastrointest Cancer 2019;50:716-22. [PMID: 29984382 DOI: 10.1007/s12029-018-0136-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
465 Klinakis A, Rampias T. TP53 mutational landscape of metastatic head and neck cancer reveals patterns of mutation selection. EBioMedicine 2020;58:102905. [PMID: 32739866 DOI: 10.1016/j.ebiom.2020.102905] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
466 Obermajer N, Urban J, Wieckowski E, Muthuswamy R, Ravindranathan R, Bartlett DL, Kalinski P. Promoting the accumulation of tumor-specific T cells in tumor tissues by dendritic cell vaccines and chemokine-modulating agents. Nat Protoc 2018;13:335-57. [PMID: 29345636 DOI: 10.1038/nprot.2017.130] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
467 Sato H, Niimi A, Yasuhara T, Permata TBM, Hagiwara Y, Isono M, Nuryadi E, Sekine R, Oike T, Kakoti S, Yoshimoto Y, Held KD, Suzuki Y, Kono K, Miyagawa K, Nakano T, Shibata A. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. Nat Commun 2017;8:1751. [PMID: 29170499 DOI: 10.1038/s41467-017-01883-9] [Cited by in Crossref: 206] [Cited by in F6Publishing: 208] [Article Influence: 41.2] [Reference Citation Analysis]
468 Eso Y, Shimizu T, Takeda H, Takai A, Marusawa H. Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers. J Gastroenterol 2020;55:15-26. [PMID: 31494725 DOI: 10.1007/s00535-019-01620-7] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 12.3] [Reference Citation Analysis]
469 Song D, Powles T, Shi L, Zhang L, Ingersoll MA, Lu YJ. Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches. J Pathol 2019;249:151-65. [PMID: 31102277 DOI: 10.1002/path.5306] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 8.3] [Reference Citation Analysis]
470 Song M, Nishihara R, Cao Y, Chun E, Qian ZR, Mima K, Inamura K, Masugi Y, Nowak JA, Nosho K, Wu K, Wang M, Giovannucci E, Garrett WS, Fuchs CS, Ogino S, Chan AT. Marine ω-3 Polyunsaturated Fatty Acid Intake and Risk of Colorectal Cancer Characterized by Tumor-Infiltrating T Cells. JAMA Oncol 2016;2:1197-206. [PMID: 27148825 DOI: 10.1001/jamaoncol.2016.0605] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 9.4] [Reference Citation Analysis]
471 Choucair K, Radford M, Bansal A, Park R, Saeed A. Advances in immune therapies for the treatment of microsatellite instability‑high/deficient mismatch repair metastatic colorectal cancer (Review). Int J Oncol 2021;59:74. [PMID: 34396449 DOI: 10.3892/ijo.2021.5254] [Reference Citation Analysis]
472 Alkan A, Hofving T, Angenete E, Yrlid U. Biomarkers and cell-based models to predict the outcome of neoadjuvant therapy for rectal cancer patients. Biomark Res 2021;9:60. [PMID: 34321074 DOI: 10.1186/s40364-021-00313-9] [Reference Citation Analysis]
473 Faisal MS, Burke CA, Liska D, Lightner AL, Leach B, O’Malley M, LaGuardia L, Click B, Achkar J, Kalady M, Church J, Mankaney G. Association of cancer with comorbid inflammatory conditions and treatment in patients with Lynch syndrome. World J Clin Oncol 2022; 13(1): 49-61 [DOI: 10.5306/wjco.v13.i1.49] [Reference Citation Analysis]
474 Ratti M, Lampis A, Hahne JC, Passalacqua R, Valeri N. Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches. Cell Mol Life Sci. 2018;75:4151-4162. [PMID: 30173350 DOI: 10.1007/s00018-018-2906-9] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 13.5] [Reference Citation Analysis]
475 Wang L, Zhang Q, Ni S, Tan C, Cai X, Huang D, Sheng W. Programmed death-ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2-negative status. Cancer Med. 2018;7:2612-2620. [PMID: 29673110 DOI: 10.1002/cam4.1502] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 6.5] [Reference Citation Analysis]
476 Blair TC, Alice AF, Zebertavage L, Crittenden MR, Gough MJ. The Dynamic Entropy of Tumor Immune Infiltrates: The Impact of Recirculation, Antigen-Specific Interactions, and Retention on T Cells in Tumors. Front Oncol 2021;11:653625. [PMID: 33968757 DOI: 10.3389/fonc.2021.653625] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
477 Goyal G, Fan T, Silberstein PT. Hereditary cancer syndromes: utilizing DNA repair deficiency as therapeutic target. Fam Cancer. 2016;15:359-366. [PMID: 26873719 DOI: 10.1007/s10689-016-9883-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
478 Nöpel-Dünnebacke S, Conradi LC, Reinacher-Schick A, Ghadimi M. [Influence of molecular markers on oncological surgery of colorectal cancer]. Chirurg 2021;92:986-95. [PMID: 34448902 DOI: 10.1007/s00104-021-01486-7] [Reference Citation Analysis]
479 Koustas E, Papavassiliou AG, Karamouzis MV. The role of autophagy in the treatment of BRAF mutant colorectal carcinomas differs based on microsatellite instability status. PLoS One 2018;13:e0207227. [PMID: 30427914 DOI: 10.1371/journal.pone.0207227] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
480 Kanat O, O’Neil B, Shahda S. Targeted therapy for advanced gastric cancer: A review of current status and future prospects. World J Gastrointest Oncol 2015; 7(12): 401-410 [PMID: 26690491 DOI: 10.4251/wjgo.v7.i12.401] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
481 Gunderson AJ, Young KH. Exploring optimal sequencing of radiation and immunotherapy combinations. Adv Radiat Oncol 2018;3:494-505. [PMID: 30370348 DOI: 10.1016/j.adro.2018.07.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
482 Wang C, Chevalier D, Saluja J, Sandhu J, Lau C, Fakih M. Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer. Oncologist 2020;25:e1188-94. [PMID: 32406541 DOI: 10.1634/theoncologist.2020-0161] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
483 Chen KH, Yuan CT, Tseng LH, Shun CT, Yeh KH. Case report: mismatch repair proficiency and microsatellite stability in gastric cancer may not predict programmed death-1 blockade resistance. J Hematol Oncol 2016;9:29. [PMID: 27012666 DOI: 10.1186/s13045-016-0259-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
484 Ahmad R, Singh JK, Wunnava A, Al-Obeed O, Abdulla M, Srivastava SK. Emerging trends in colorectal cancer: Dysregulated signaling pathways (Review). Int J Mol Med. 2021;47. [PMID: 33655327 DOI: 10.3892/ijmm.2021.4847] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
485 Matsuoka T, Yashiro M. Precision medicine for gastrointestinal cancer: Recent progress and future perspective. World J Gastrointest Oncol 2020; 12(1): 1-20 [PMID: 31966910 DOI: 10.4251/wjgo.v12.i1.1] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
486 Oliveira AF, Bretes L, Furtado I. Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer. Front Oncol 2019;9:396. [PMID: 31139574 DOI: 10.3389/fonc.2019.00396] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 16.0] [Reference Citation Analysis]
487 Yu G, Wu Y, Wang W, Xu J, Lv X, Cao X, Wan T. Low-dose decitabine enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by re-modulating the tumor microenvironment. Cell Mol Immunol 2019;16:401-9. [PMID: 29622799 DOI: 10.1038/s41423-018-0026-y] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 10.5] [Reference Citation Analysis]
488 Das A, Sudhaman S, Morgenstern D, Coblentz A, Chung J, Stone SC, Alsafwani N, Liu ZA, Karsaneh OAA, Soleimani S, Ladany H, Chen D, Zatzman M, Cabric V, Nobre L, Bianchi V, Edwards M, Sambira Nahum LC, Ercan AB, Nabbi A, Constantini S, Dvir R, Yalon-Oren M, Campino GA, Caspi S, Larouche V, Reddy A, Osborn M, Mason G, Lindhorst S, Bronsema A, Magimairajan V, Opocher E, De Mola RL, Sabel M, Frojd C, Sumerauer D, Samuel D, Cole K, Chiaravalli S, Massimino M, Tomboc P, Ziegler DS, George B, Van Damme A, Hijiya N, Gass D, McGee RB, Mordechai O, Bowers DC, Laetsch TW, Lossos A, Blumenthal DT, Sarosiek T, Yen LY, Knipstein J, Bendel A, Hoffman LM, Luna-Fineman S, Zimmermann S, Scheers I, Nichols KE, Zapotocky M, Hansford JR, Maris JM, Dirks P, Taylor MD, Kulkarni AV, Shroff M, Tsang DS, Villani A, Xu W, Aronson M, Durno C, Shlien A, Malkin D, Getz G, Maruvka YE, Ohashi PS, Hawkins C, Pugh TJ, Bouffet E, Tabori U. Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency. Nat Med 2022. [PMID: 34992263 DOI: 10.1038/s41591-021-01581-6] [Reference Citation Analysis]
489 Wang YL, Gong Y, Lv Z, Li L, Yuan Y. Expression of PD1/PDL1 in gastric cancer at different microsatellite status and its correlation with infiltrating immune cells in the tumor microenvironment. J Cancer 2021;12:1698-707. [PMID: 33613757 DOI: 10.7150/jca.40500] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
490 Smith KN, Llosa NJ, Cottrell TR, Siegel N, Fan H, Suri P, Chan HY, Guo H, Oke T, Awan AH, Verde F, Danilova L, Anagnostou V, Tam AJ, Luber BS, Bartlett BR, Aulakh LK, Sidhom JW, Zhu Q, Sears CL, Cope L, Sharfman WH, Thompson ED, Riemer J, Marrone KA, Naidoo J, Velculescu VE, Forde PM, Vogelstein B, Kinzler KW, Papadopoulos N, Durham JN, Wang H, Le DT, Justesen S, Taube JM, Diaz LA Jr, Brahmer JR, Pardoll DM, Anders RA, Housseau F. Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1. J Immunother Cancer 2019;7:40. [PMID: 30744692 DOI: 10.1186/s40425-018-0492-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 7.7] [Reference Citation Analysis]
491 Shia J, Schultz N, Kuk D, Vakiani E, Middha S, Segal NH, Hechtman JF, Berger MF, Stadler ZK, Weiser MR, Wolchok JD, Boland CR, Gönen M, Klimstra DS. Morphological characterization of colorectal cancers in The Cancer Genome Atlas reveals distinct morphology-molecular associations: clinical and biological implications. Mod Pathol 2017;30:599-609. [PMID: 27982025 DOI: 10.1038/modpathol.2016.198] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 6.3] [Reference Citation Analysis]
492 Inoue A, Deem AK, Kopetz S, Heffernan TP, Draetta GF, Carugo A. Current and Future Horizons of Patient-Derived Xenograft Models in Colorectal Cancer Translational Research. Cancers (Basel) 2019;11:E1321. [PMID: 31500168 DOI: 10.3390/cancers11091321] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
493 Viale G, Trapani D, Curigliano G. Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy. Biomed Res Int. 2017;2017:4719194. [PMID: 28770222 DOI: 10.1155/2017/4719194] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 7.8] [Reference Citation Analysis]
494 Gruber ES, Oberhuber G, Pils D, Stork T, Sinn K, Gruber S, Nica R, Kolmer D, Turner SD, Schlederer M, Widder J, Doerr W, Teleky B, Kenner L. The Determination of Immunomodulation and Its Impact on Survival of Rectal Cancer Patients Depends on the Area Comprising a Tissue Microarray. Cancers (Basel) 2020;12:E563. [PMID: 32121328 DOI: 10.3390/cancers12030563] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
495 Ooki A, Shinozaki E, Yamaguchi K. Immunotherapy in Colorectal Cancer: Current and Future Strategies. J Anus Rectum Colon 2021;5:11-24. [PMID: 33537496 DOI: 10.23922/jarc.2020-064] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
496 Cantero-Cid R, Casas-Martin J, Hernández-Jiménez E, Cubillos-Zapata C, Varela-Serrano A, Avendaño-Ortiz J, Casarrubios M, Montalbán-Hernández K, Villacañas-Gil I, Guerra-Pastrián L, Peinado B, Marcano C, Aguirre LA, López-Collazo E. PD-L1/PD-1 crosstalk in colorectal cancer: are we targeting the right cells? BMC Cancer 2018;18:945. [PMID: 30285662 DOI: 10.1186/s12885-018-4853-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
497 Ruess DA, Görgülü K, Wörmann SM, Algül H. Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts. Drugs Aging 2017;34:331-57. [PMID: 28349415 DOI: 10.1007/s40266-017-0453-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
498 Kreidieh M, Mukherji D, Temraz S, Shamseddine A. Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions. Biomed Res Int 2020;2020:9037217. [PMID: 32090113 DOI: 10.1155/2020/9037217] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
499 Eso Y, Seno H. Current status of treatment with immune checkpoint inhibitors for gastrointestinal, hepatobiliary, and pancreatic cancers. Therap Adv Gastroenterol. 2020;13:1756284820948773. [PMID: 32913444 DOI: 10.1177/1756284820948773] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
500 Zarour HM. Reversing T-cell Dysfunction and Exhaustion in Cancer. Clin Cancer Res. 2016;22:1856-1864. [PMID: 27084739 DOI: 10.1158/1078-0432.ccr-15-1849] [Cited by in Crossref: 186] [Cited by in F6Publishing: 120] [Article Influence: 31.0] [Reference Citation Analysis]
501 Ciombor KK, Goldberg RM. Hypermutated Tumors and Immune Checkpoint Inhibition. Drugs 2018;78:155-62. [PMID: 29350327 DOI: 10.1007/s40265-018-0863-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
502 Chae YK, Wang S, Nimeiri H, Kalyan A, Giles FJ. Pseudoprogression in microsatellite instability-high colorectal cancer during treatment with combination T cell mediated immunotherapy: a case report and literature review. Oncotarget. 2017;8:57889-57897. [PMID: 28915720 DOI: 10.18632/oncotarget.18361] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
503 Ji Z, Peng Z, Gong J, Zhang X, Li J, Lu M, Lu Z, Shen L. Hyperprogression after immunotherapy in patients with malignant tumors of digestive system. BMC Cancer 2019;19:705. [PMID: 31315610 DOI: 10.1186/s12885-019-5921-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
504 Kallenbach-Thieltges A, Großerueschkamp F, Jütte H, Kuepper C, Reinacher-Schick A, Tannapfel A, Gerwert K. Label-free, automated classification of microsatellite status in colorectal cancer by infrared imaging. Sci Rep 2020;10:10161. [PMID: 32576892 DOI: 10.1038/s41598-020-67052-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
505 Choi SH, Barker EC, Gerber KJ, Letterio JJ, Kim BG. Loss of p27Kip1 leads to expansion of CD4+ effector memory T cells and accelerates colitis-associated colon cancer in mice with a T cell lineage restricted deletion of Smad4. Oncoimmunology 2020;9:1847832. [PMID: 33329939 DOI: 10.1080/2162402X.2020.1847832] [Reference Citation Analysis]
506 Xiao W, Ibrahim ML, Redd PS, Klement JD, Lu C, Yang D, Savage NM, Liu K. Loss of Fas Expression and Function Is Coupled with Colon Cancer Resistance to Immune Checkpoint Inhibitor Immunotherapy. Mol Cancer Res 2019;17:420-30. [PMID: 30429213 DOI: 10.1158/1541-7786.MCR-18-0455] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
507 Shuford RA, Cairns AL, Moaven O. Precision Approaches in the Management of Colorectal Cancer: Current Evidence and Latest Advancements Towards Individualizing the Treatment. Cancers (Basel) 2020;12:E3481. [PMID: 33238500 DOI: 10.3390/cancers12113481] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
508 Toomey S, Gunther J, Carr A, Weksberg DC, Thomas V, Salvucci M, Bacon O, Sherif EM, Fay J, Kay EW, Sheehan KM, McNamara DA, Sanders KL, Mathew G, Breathnach OS, Grogan L, Morris PG, Foo WC, You YN, Prehn JH, O'Neill B, Krishnan S, Hennessy BT, Furney SJ. Genomic and Transcriptomic Characterisation of Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. Cancers (Basel). 2020;12. [PMID: 32640573 DOI: 10.3390/cancers12071808] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
509 Toor SM, Sasidharan Nair V, Murshed K, Abu Nada M, Elkord E. Tumor-Infiltrating Lymphoid Cells in Colorectal Cancer Patients with Varying Disease Stages and Microsatellite Instability-High/Stable Tumors. Vaccines (Basel) 2021;9:64. [PMID: 33477864 DOI: 10.3390/vaccines9010064] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
510 Bao C, An N, Xie H, Xu L, Zhou B, Luo J, Huang W, Huang J. Identifying Potential Neoantigens for Cervical Cancer Immunotherapy Using Comprehensive Genomic Variation Profiling of Cervical Intraepithelial Neoplasia and Cervical Cancer. Front Oncol 2021;11:672386. [PMID: 34221990 DOI: 10.3389/fonc.2021.672386] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
511 Cohen R, Bennouna J, Meurisse A, Tournigand C, De La Fouchardière C, Tougeron D, Borg C, Mazard T, Chibaudel B, Garcia-Larnicol ML, Svrcek M, Vernerey D, Menu Y, André T. RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study. J Immunother Cancer 2020;8:e001499. [PMID: 33148693 DOI: 10.1136/jitc-2020-001499] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
512 Llosa NJ, Luber B, Tam AJ, Smith KN, Siegel N, Awan AH, Fan H, Oke T, Zhang J, Domingue J, Engle EL, Roberts CA, Bartlett BR, Aulakh LK, Thompson ED, Taube JM, Durham JN, Sears CL, Le DT, Diaz LA, Pardoll DM, Wang H, Anders RA, Housseau F. Intratumoral Adaptive Immunosuppression and Type 17 Immunity in Mismatch Repair Proficient Colorectal Tumors. Clin Cancer Res. 2019;25:5250-5259. [PMID: 31061070 DOI: 10.1158/1078-0432.ccr-19-0114] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 6.7] [Reference Citation Analysis]
513 Chen J, Apizi A, Wang L, Wu G, Zhu Z, Yao H, Chen G, Shi X, Shi B, Tai Q, Shen C, Zhou G, Wu L, He S. TCGA database analysis of the tumor mutation burden and its clinical significance in colon cancer. J Gastrointest Oncol 2021;12:2244-59. [PMID: 34790389 DOI: 10.21037/jgo-21-661] [Reference Citation Analysis]
514 Wang C, Park J, Ouyang C, Longmate JA, Tajon M, Chao J, Lim D, Sandhu J, Yin HH, Pillai R, Gozo MC, Avalos C, Egelston CA, Lee PP, Fakih M. A Pilot Feasibility Study of Yttrium-90 Liver Radioembolization Followed by Durvalumab and Tremelimumab in Patients with Microsatellite Stable Colorectal Cancer Liver Metastases. Oncologist 2020;25:382-e776. [PMID: 31857446 DOI: 10.1634/theoncologist.2019-0924] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
515 Baliu-Piqué M, Pandiella A, Ocana A. Breast Cancer Heterogeneity and Response to Novel Therapeutics. Cancers (Basel) 2020;12:E3271. [PMID: 33167363 DOI: 10.3390/cancers12113271] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
516 Wang C, Sandhu J, Ouyang C, Ye J, Lee PP, Fakih M. Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases. JAMA Netw Open 2021;4:e2118416. [PMID: 34369992 DOI: 10.1001/jamanetworkopen.2021.18416] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
517 Wang L, Hui H, Agrawal K, Kang Y, Li N, Tang R, Yuan J, Rana TM. m6 A RNA methyltransferases METTL3/14 regulate immune responses to anti-PD-1 therapy. EMBO J 2020;39:e104514. [PMID: 32964498 DOI: 10.15252/embj.2020104514] [Cited by in Crossref: 28] [Cited by in F6Publishing: 38] [Article Influence: 14.0] [Reference Citation Analysis]
518 Shen Y, Guan Y, Hummel JJ, Shyu CR, Mitchem JB. Immunogenomic pathways associated with cytotoxic lymphocyte infiltration and survival in colorectal cancer. BMC Cancer 2020;20:124. [PMID: 32059711 DOI: 10.1186/s12885-020-6513-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
519 Li X, Shao C, Shi Y, Han W. Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. J Hematol Oncol. 2018;11:31. [PMID: 29482595 DOI: 10.1186/s13045-018-0578-4] [Cited by in Crossref: 102] [Cited by in F6Publishing: 102] [Article Influence: 25.5] [Reference Citation Analysis]
520 Germano G, Lamba S, Rospo G, Barault L, Magrì A, Maione F, Russo M, Crisafulli G, Bartolini A, Lerda G, Siravegna G, Mussolin B, Frapolli R, Montone M, Morano F, de Braud F, Amirouchene-Angelozzi N, Marsoni S, D'Incalci M, Orlandi A, Giraudo E, Sartore-Bianchi A, Siena S, Pietrantonio F, Di Nicolantonio F, Bardelli A. Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Nature 2017;552:116-20. [PMID: 29186113 DOI: 10.1038/nature24673] [Cited by in Crossref: 239] [Cited by in F6Publishing: 222] [Article Influence: 47.8] [Reference Citation Analysis]
521 Tu C, Wang Y, Cheng X, Zhu Y, Yuan W, Dong J. The Combination Therapy of Fluorouracil and Oxaliplatin Suppress the Progression of Colon Cancer Through miR-183-5p/SOCS3 Axis and Downregulating PD-L1. Cancer Manag Res 2021;13:1999-2008. [PMID: 33658858 DOI: 10.2147/CMAR.S281925] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
522 Køstner AH, Nielsen PS, Georgsen JB, Parner ET, Nielsen MB, Kersten C, Steiniche T. Systemic Inflammation Associates With a Myeloid Inflamed Tumor Microenvironment in Primary Resected Colon Cancer-May Cold Tumors Simply Be Too Hot? Front Immunol 2021;12:716342. [PMID: 34531864 DOI: 10.3389/fimmu.2021.716342] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
523 Wang C, Gong J, Tu TY, Lee PP, Fakih M. Immune profiling of microsatellite instability-high and polymerase ε (POLE)-mutated metastatic colorectal tumors identifies predictors of response to anti-PD-1 therapy. J Gastrointest Oncol 2018;9:404-15. [PMID: 29998005 DOI: 10.21037/jgo.2018.01.09] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
524 Song Y, Huang J, Liang D, Hu Y, Mao B, Li Q, Sun H, Yang Y, Zhang J, Zhang H, Chen H, Liu H, Zhang S. DNA Damage Repair Gene Mutations Are Indicative of a Favorable Prognosis in Colorectal Cancer Treated With Immune Checkpoint Inhibitors. Front Oncol 2020;10:549777. [PMID: 33680909 DOI: 10.3389/fonc.2020.549777] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
525 Zhang Q, Feng Z, Zhang Y, Shi S, Zhang Y, Ren S. Identification and Verification of a 17 Immune-Related Gene Pair Prognostic Signature for Colon Cancer. Biomed Res Int 2021;2021:6057948. [PMID: 34124251 DOI: 10.1155/2021/6057948] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
526 Principe DR, DeCant B, Staudacher J, Vitello D, Mangan RJ, Wayne EA, Mascariñas E, Diaz AM, Bauer J, McKinney RD, Khazaie K, Pasche B, Dawson DW, Munshi HG, Grippo PJ, Jung B. Loss of TGFβ signaling promotes colon cancer progression and tumor-associated inflammation. Oncotarget 2017;8:3826-39. [PMID: 27270652 DOI: 10.18632/oncotarget.9830] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
527 Gmeiner WH. Fluoropyrimidine Modulation of the Anti-Tumor Immune Response-Prospects for Improved Colorectal Cancer Treatment. Cancers (Basel) 2020;12:E1641. [PMID: 32575843 DOI: 10.3390/cancers12061641] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]